<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">84790</article-id><article-id pub-id-type="doi">10.7554/eLife.84790</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>SARS-CoV-2 uses CD4 to infect T helper lymphocytes</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-178447"><name><surname>Brunetti</surname><given-names>Natalia S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2803-3763</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund27"/><xref ref-type="other" rid="fund28"/><xref ref-type="other" rid="fund29"/><xref ref-type="other" rid="fund30"/><xref ref-type="other" rid="fund31"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-302632"><name><surname>Davanzo</surname><given-names>Gustavo G</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-302639"><name><surname>de Moraes</surname><given-names>Diogo</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-102452"><name><surname>Ferrari</surname><given-names>Allan JR</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9199-2257</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-302642"><name><surname>Souza</surname><given-names>Gabriela F</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-223394"><name><surname>Muraro</surname><given-names>Stéfanie Primon</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5105-6659</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-302643"><name><surname>Knittel</surname><given-names>Thiago L</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund32"/><xref ref-type="other" rid="fund33"/><xref ref-type="other" rid="fund34"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-178440"><name><surname>Boldrini</surname><given-names>Vinicius O</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-302644"><name><surname>Monteiro</surname><given-names>Lauar B</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-302645"><name><surname>Virgílio-da-Silva</surname><given-names>João Victor</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-302646"><name><surname>Profeta</surname><given-names>Gerson S</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-302647"><name><surname>Wassano</surname><given-names>Natália S</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-260734"><name><surname>Nunes Santos</surname><given-names>Luana</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0092-0803</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-302648"><name><surname>Carregari</surname><given-names>Victor C</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-302649"><name><surname>Dias</surname><given-names>Artur HS</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302650"><name><surname>Veras</surname><given-names>Flavio P</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302651"><name><surname>Tavares</surname><given-names>Lucas A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7883-1443</contrib-id><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223393"><name><surname>Forato</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-257777"><name><surname>Castro</surname><given-names>Icaro MS</given-names></name><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302652"><name><surname>Silva-Costa</surname><given-names>Lícia C</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302653"><name><surname>Palma</surname><given-names>André C</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302654"><name><surname>Mansour</surname><given-names>Eli</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6450-6930</contrib-id><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302655"><name><surname>Ulaf</surname><given-names>Raisa G</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302656"><name><surname>Bernardes</surname><given-names>Ana F</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302657"><name><surname>Nunes</surname><given-names>Thyago A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0202-0550</contrib-id><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con25"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302658"><name><surname>Ribeiro</surname><given-names>Luciana C</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con26"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302659"><name><surname>Agrela</surname><given-names>Marcus V</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con27"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302660"><name><surname>Moretti</surname><given-names>Maria Luiza</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con28"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302661"><name><surname>Buscaratti</surname><given-names>Lucas I</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con29"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302662"><name><surname>Crunfli</surname><given-names>Fernanda</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con30"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302663"><name><surname>Ludwig</surname><given-names>Raissa G</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con31"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302664"><name><surname>Gerhardt</surname><given-names>Jaqueline A</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con32"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302665"><name><surname>Munhoz-Alves</surname><given-names>Natália</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2756-3666</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con33"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-178441"><name><surname>Marques</surname><given-names>Ana Maria</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con34"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302666"><name><surname>Sesti-Costa</surname><given-names>Renata</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="fn" rid="con35"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223392"><name><surname>Amorim</surname><given-names>Mariene R</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con36"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223385"><name><surname>Toledo-Teixeira</surname><given-names>Daniel A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4055-058X</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con37"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223381"><name><surname>Parise</surname><given-names>Pierina Lorencini</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con38"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223396"><name><surname>Martini</surname><given-names>Matheus Cavalheiro</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con39"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223397"><name><surname>Bispos-dos-Santos</surname><given-names>Karina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0305-367X</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con40"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302668"><name><surname>Simeoni</surname><given-names>Camila L</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con41"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302669"><name><surname>Granja</surname><given-names>Fabiana</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con42"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302670"><name><surname>Silvestrini</surname><given-names>Virgínia C</given-names></name><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="fn" rid="con43"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302671"><name><surname>de Oliveira</surname><given-names>Eduardo B</given-names></name><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="fn" rid="con44"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-232838"><name><surname>Faca</surname><given-names>Vitor M</given-names></name><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="fn" rid="con45"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302744"><name><surname>Carvalho</surname><given-names>Murilo</given-names></name><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="aff" rid="aff19">19</xref><xref ref-type="fn" rid="con46"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302745"><name><surname>Castelucci</surname><given-names>Bianca G</given-names></name><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="aff" rid="aff19">19</xref><xref ref-type="fn" rid="con47"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302746"><name><surname>Pereira</surname><given-names>Alexandre B</given-names></name><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="fn" rid="con48"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302747"><name><surname>Coimbra</surname><given-names>Laís D</given-names></name><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="fn" rid="con49"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302748"><name><surname>Dias</surname><given-names>Marieli MG</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0246-8884</contrib-id><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="fn" rid="con50"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302749"><name><surname>Rodrigues</surname><given-names>Patricia B</given-names></name><xref ref-type="aff" rid="aff20">20</xref><xref ref-type="fn" rid="con51"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302750"><name><surname>Gomes</surname><given-names>Arilson Bernardo SP</given-names></name><xref ref-type="aff" rid="aff20">20</xref><xref ref-type="fn" rid="con52"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302751"><name><surname>Pereira</surname><given-names>Fabricio B</given-names></name><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="fn" rid="con53"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-178455"><name><surname>Santos</surname><given-names>Leonilda MB</given-names></name><xref ref-type="aff" rid="aff21">21</xref><xref ref-type="aff" rid="aff22">22</xref><xref ref-type="fn" rid="con54"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302752"><name><surname>Bloyet</surname><given-names>Louis-Marie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5648-3190</contrib-id><xref ref-type="aff" rid="aff23">23</xref><xref ref-type="fn" rid="con55"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302753"><name><surname>Stumpf</surname><given-names>Spencer</given-names></name><xref ref-type="aff" rid="aff23">23</xref><xref ref-type="fn" rid="con56"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302759"><name><surname>Pontelli</surname><given-names>Marjorie C</given-names></name><xref ref-type="aff" rid="aff23">23</xref><xref ref-type="fn" rid="con57"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-187366"><name><surname>Whelan</surname><given-names>Sean</given-names></name><xref ref-type="aff" rid="aff23">23</xref><xref ref-type="fn" rid="con58"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302754"><name><surname>Sposito</surname><given-names>Andrei C</given-names></name><xref ref-type="aff" rid="aff24">24</xref><xref ref-type="fn" rid="con59"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302756"><name><surname>Carvalho</surname><given-names>Robson F</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4901-7714</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con60"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302757"><name><surname>Vieira</surname><given-names>André S</given-names></name><xref ref-type="aff" rid="aff25">25</xref><xref ref-type="fn" rid="con61"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302758"><name><surname>Vinolo</surname><given-names>Marco AR</given-names></name><xref ref-type="aff" rid="aff20">20</xref><xref ref-type="aff" rid="aff26">26</xref><xref ref-type="aff" rid="aff27">27</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund15"/><xref ref-type="other" rid="fund16"/><xref ref-type="other" rid="fund17"/><xref ref-type="other" rid="fund18"/><xref ref-type="other" rid="fund19"/><xref ref-type="fn" rid="con62"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302755"><name><surname>Damasio</surname><given-names>André</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff26">26</xref><xref ref-type="fn" rid="con63"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-221189"><name><surname>Velloso</surname><given-names>Licio</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="aff" rid="aff27">27</xref><xref ref-type="fn" rid="con64"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302739"><name><surname>Figueira</surname><given-names>Ana Carolina M</given-names></name><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund25"/><xref ref-type="other" rid="fund26"/><xref ref-type="fn" rid="con65"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-92145"><name><surname>da Silva</surname><given-names>Luis LP</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3558-0087</contrib-id><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con66"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-59053"><name><surname>Cunha</surname><given-names>Thiago Mattar</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1084-0065</contrib-id><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con67"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-127503"><name><surname>Nakaya</surname><given-names>Helder I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5297-9108</contrib-id><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund20"/><xref ref-type="other" rid="fund21"/><xref ref-type="other" rid="fund22"/><xref ref-type="other" rid="fund23"/><xref ref-type="other" rid="fund24"/><xref ref-type="fn" rid="con68"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-89241"><name><surname>Marques-Souza</surname><given-names>Henrique</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5008-8413</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con69"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302742"><name><surname>Marques</surname><given-names>Rafael E</given-names></name><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con70"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-81467"><name><surname>Martins-de-Souza</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff26">26</xref><xref ref-type="aff" rid="aff28">28</xref><xref ref-type="aff" rid="aff29">29</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="fn" rid="con71"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302640"><name><surname>Skaf</surname><given-names>Munir S</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con72"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-220843"><name><surname>Proenca-Modena</surname><given-names>Jose Luiz</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4996-3153</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff26">26</xref><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="fn" rid="con73"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302641"><name><surname>Moraes-Vieira</surname><given-names>Pedro MM</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff26">26</xref><xref ref-type="aff" rid="aff27">27</xref><xref ref-type="fn" rid="con74"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-81792"><name><surname>Mori</surname><given-names>Marcelo A</given-names></name><email>morima@unicamp.br</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff26">26</xref><xref ref-type="aff" rid="aff27">27</xref><xref ref-type="other" rid="fund35"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con75"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-178203"><name><surname>Farias</surname><given-names>Alessandro S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6759-1819</contrib-id><email>asfarias@unicamp.br</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff23">23</xref><xref ref-type="aff" rid="aff26">26</xref><xref ref-type="aff" rid="aff27">27</xref><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund35"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con76"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Autoimmune Research Laboratory, Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Laboratory of Immunometabolism, Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Laboratory of Aging Biology, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00987cb86</institution-id><institution>Department of Structural and Functional Biology, Institute of Biosciences, Sao Paulo State University (UNESP)</institution></institution-wrap><addr-line><named-content content-type="city">Botucatu</named-content></addr-line><country>Brazil</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Institute of Chemistry and Center for Computing in Engineering and Sciences, University of Campinas, Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Laboratory of Emerging Viruses, Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Brazilian Laboratory on Silencing Technologies (BLaST), Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>Center of Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>Department of BioMolecular Sciences, School of Pharmaceutical Sciences, University of São Paulo, Ribeirão Preto</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto,</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>Department of Cell and Molecular Biology, Center for Virology Research, Ribeirão Preto Medical School, University of São Paulo</institution></institution-wrap><addr-line><named-content content-type="city">Ribeirão Preto</named-content></addr-line><country>Brazil</country></aff><aff id="aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Department of Internal Medicine, School of Medical Sciences, University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Hematology and Hemotherapy Center, University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo</institution></institution-wrap><addr-line><named-content content-type="city">Ribeirão Preto</named-content></addr-line><country>Brazil</country></aff><aff id="aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05m235j20</institution-id><institution>National Biosciences Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01p6gzq21</institution-id><institution>Brazilian Synchrotron Light Laboratory (LNLS), Brazilian Center for Research in Energy and Materials (CNPEM)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Laboratory of Immunoinflammation, Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil;</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Neuroimmunology Unit, Department of Genetics, Microbiology and Immunology, University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04jhswv08</institution-id><institution>National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM) – Oswaldo Cruz Institute, Oswaldo Cruz Foundation</institution></institution-wrap><addr-line><named-content content-type="city">Rio de Janeiro</named-content></addr-line><country>Brazil</country></aff><aff id="aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Washington University in St Louis, Department of Molecular Microbiology</institution></institution-wrap><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff><aff id="aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Laboratory of Vascular Biology and Arteriosclerosis, School of Medical Sciences, University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff25"><label>25</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Laboratory of Electrophysiology, Neurobiology and Behavior, University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff26"><label>26</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Experimental Medicine Research Cluster (EMRC), University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff27"><label>27</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>Obesity and Comorbidities Research Center (OCRC), University of Campinas (UNICAMP)</institution></institution-wrap><addr-line><named-content content-type="city">Campinas</named-content></addr-line><country>Brazil</country></aff><aff id="aff28"><label>28</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01mar7r17</institution-id><institution>D'Or Institute for Research and Education (IDOR)</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff29"><label>29</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/045ydbe97</institution-id><institution>National Institute of Science and Technology in Biomarkers for Neuropsychiatry (INCTINBION)</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>van de Veerdonk</surname><given-names>Frank L</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Radboud University Nijmegen Medical Centre</institution></institution-wrap><country>Netherlands</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>van der Meer</surname><given-names>Jos W</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/016xsfp80</institution-id><institution>Radboud University Medical Centre</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="con" id="equal-contrib2"><label>‡</label><p>These authors also contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>31</day><month>07</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e84790</elocation-id><history><date date-type="received" iso-8601-date="2022-11-30"><day>30</day><month>11</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-07-13"><day>13</day><month>07</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2020-09-28"><day>28</day><month>09</month><year>2020</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2020.09.25.20200329"/></event></pub-history><permissions><copyright-statement>© 2023, Brunetti, Davanzo, de Moraes et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Brunetti, Davanzo, de Moraes et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-84790-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-84790-figures-v1.pdf"/><abstract><p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent of a major global outbreak of respiratory tract disease known as Coronavirus Disease 2019 (COVID-19). SARS-CoV-2 infects mainly lungs and may cause several immune-related complications, such as lymphocytopenia and cytokine storm, which are associated with the severity of the disease and predict mortality. The mechanism by which SARS-CoV-2 infection may result in immune system dysfunction is still not fully understood. Here, we show that SARS-CoV-2 infects human CD4<sup>+</sup> T helper cells, but not CD8<sup>+</sup> T cells, and is present in blood and bronchoalveolar lavage T helper cells of severe COVID-19 patients. We demonstrated that SARS-CoV-2 spike glycoprotein (S) directly binds to the CD4 molecule, which in turn mediates the entry of SARS- CoV-2 in T helper cells. This leads to impaired CD4 T cell function and may cause cell death. SARS-CoV-2-infected T helper cells express higher levels of IL-10, which is associated with viral persistence and disease severity. Thus, CD4-mediated SARS-CoV-2 infection of T helper cells may contribute to a poor immune response in COVID-19 patients.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>COVID-19</kwd><kwd>T cells</kwd><kwd>virus infection</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006417</institution-id><institution>Fundo de Apoio ao Ensino, à Pesquisa e Extensão, Universidade Estadual de Campinas</institution></institution-wrap></funding-source><award-id>#2295/20</award-id><principal-award-recipient><name><surname>Boldrini</surname><given-names>Vinicius O</given-names></name><name><surname>Nunes Santos</surname><given-names>Luana</given-names></name><name><surname>Martins-de-Souza</surname><given-names>Daniel</given-names></name><name><surname>Proenca-Modena</surname><given-names>Jose Luiz</given-names></name><name><surname>Farias</surname><given-names>Alessandro S</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2021/08354-2</award-id><principal-award-recipient><name><surname>Vinolo</surname><given-names>Marco AR</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2015/15626-8</award-id><principal-award-recipient><name><surname>Nakaya</surname><given-names>Helder I</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2019/14465-1</award-id><principal-award-recipient><name><surname>Figueira</surname><given-names>Ana Carolina M</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100018824</institution-id><institution>Instituto Nacional de Ciência e Tecnologia em Neuroimunomodulação</institution></institution-wrap></funding-source><award-id>#465489/2014-1</award-id><principal-award-recipient><name><surname>Farias</surname><given-names>Alessandro S</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004809</institution-id><institution>Financiadora de Estudos e Projetos</institution></institution-wrap></funding-source><award-id>#01.20.0003.00</award-id><principal-award-recipient><name><surname>Marques</surname><given-names>Rafael E</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002322</institution-id><institution>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Martins-de-Souza</surname><given-names>Daniel</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003593</institution-id><institution>Conselho Nacional de Desenvolvimento Científico e Tecnológico</institution></institution-wrap></funding-source><award-id>#306248/2017-4</award-id><principal-award-recipient><name><surname>Mori</surname><given-names>Marcelo A</given-names></name><name><surname>Farias</surname><given-names>Alessandro S</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2019/17007-4</award-id><principal-award-recipient><name><surname>Brunetti</surname><given-names>Natalia S</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2019/04726-2</award-id><principal-award-recipient><name><surname>Knittel</surname><given-names>Thiago L</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006417</institution-id><institution>Fundo de Apoio ao Ensino, à Pesquisa e Extensão, Universidade Estadual de Campinas</institution></institution-wrap></funding-source><award-id>#2319/20</award-id><principal-award-recipient><name><surname>Boldrini</surname><given-names>Vinicius O</given-names></name><name><surname>Nunes Santos</surname><given-names>Luana</given-names></name><name><surname>Martins-de-Souza</surname><given-names>Daniel</given-names></name><name><surname>Proenca-Modena</surname><given-names>Jose Luiz</given-names></name><name><surname>Farias</surname><given-names>Alessandro S</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006417</institution-id><institution>Fundo de Apoio ao Ensino, à Pesquisa e Extensão, Universidade Estadual de Campinas</institution></institution-wrap></funding-source><award-id>#2274/20</award-id><principal-award-recipient><name><surname>Boldrini</surname><given-names>Vinicius O</given-names></name><name><surname>Nunes Santos</surname><given-names>Luana</given-names></name><name><surname>Martins-de-Souza</surname><given-names>Daniel</given-names></name><name><surname>Proenca-Modena</surname><given-names>Jose Luiz</given-names></name><name><surname>Farias</surname><given-names>Alessandro S</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006417</institution-id><institution>Fundo de Apoio ao Ensino, à Pesquisa e Extensão, Universidade Estadual de Campinas</institution></institution-wrap></funding-source><award-id>#2266/20</award-id><principal-award-recipient><name><surname>Boldrini</surname><given-names>Vinicius O</given-names></name><name><surname>Nunes Santos</surname><given-names>Luana</given-names></name><name><surname>Martins-de-Souza</surname><given-names>Daniel</given-names></name><name><surname>Proenca-Modena</surname><given-names>Jose Luiz</given-names></name><name><surname>Farias</surname><given-names>Alessandro S</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006417</institution-id><institution>Fundo de Apoio ao Ensino, à Pesquisa e Extensão, Universidade Estadual de Campinas</institution></institution-wrap></funding-source><award-id>#2458/20</award-id><principal-award-recipient><name><surname>Boldrini</surname><given-names>Vinicius O</given-names></name><name><surname>Nunes Santos</surname><given-names>Luana</given-names></name><name><surname>Martins-de-Souza</surname><given-names>Daniel</given-names></name><name><surname>Proenca-Modena</surname><given-names>Jose Luiz</given-names></name><name><surname>Farias</surname><given-names>Alessandro S</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2019/16116-4</award-id><principal-award-recipient><name><surname>Vinolo</surname><given-names>Marco AR</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2019/06372-3</award-id><principal-award-recipient><name><surname>Vinolo</surname><given-names>Marco AR</given-names></name></principal-award-recipient></award-group><award-group id="fund17"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2020/04583-4</award-id><principal-award-recipient><name><surname>Vinolo</surname><given-names>Marco AR</given-names></name></principal-award-recipient></award-group><award-group id="fund18"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2013/08293-7</award-id><principal-award-recipient><name><surname>Vinolo</surname><given-names>Marco AR</given-names></name></principal-award-recipient></award-group><award-group id="fund19"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2020/04579-7</award-id><principal-award-recipient><name><surname>Vinolo</surname><given-names>Marco AR</given-names></name></principal-award-recipient></award-group><award-group id="fund20"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2018/14933-2</award-id><principal-award-recipient><name><surname>Nakaya</surname><given-names>Helder I</given-names></name></principal-award-recipient></award-group><award-group id="fund21"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2020/04746-0</award-id><principal-award-recipient><name><surname>Nakaya</surname><given-names>Helder I</given-names></name></principal-award-recipient></award-group><award-group id="fund22"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2019/00098-7</award-id><principal-award-recipient><name><surname>Nakaya</surname><given-names>Helder I</given-names></name></principal-award-recipient></award-group><award-group id="fund23"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2020/04919-2</award-id><principal-award-recipient><name><surname>Nakaya</surname><given-names>Helder I</given-names></name></principal-award-recipient></award-group><award-group id="fund24"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2017/01184-9</award-id><principal-award-recipient><name><surname>Nakaya</surname><given-names>Helder I</given-names></name></principal-award-recipient></award-group><award-group id="fund25"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2020/04558-0</award-id><principal-award-recipient><name><surname>Figueira</surname><given-names>Ana Carolina M</given-names></name></principal-award-recipient></award-group><award-group id="fund26"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2016/00194-8</award-id><principal-award-recipient><name><surname>Figueira</surname><given-names>Ana Carolina M</given-names></name></principal-award-recipient></award-group><award-group id="fund27"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2016/18031- 8</award-id><principal-award-recipient><name><surname>Brunetti</surname><given-names>Natalia S</given-names></name></principal-award-recipient></award-group><award-group id="fund28"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2019/22398-2</award-id><principal-award-recipient><name><surname>Brunetti</surname><given-names>Natalia S</given-names></name></principal-award-recipient></award-group><award-group id="fund29"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2019/13552-8</award-id><principal-award-recipient><name><surname>Brunetti</surname><given-names>Natalia S</given-names></name></principal-award-recipient></award-group><award-group id="fund30"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2019/05155-9</award-id><principal-award-recipient><name><surname>Brunetti</surname><given-names>Natalia S</given-names></name></principal-award-recipient></award-group><award-group id="fund31"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2019/06459-1</award-id><principal-award-recipient><name><surname>Brunetti</surname><given-names>Natalia S</given-names></name></principal-award-recipient></award-group><award-group id="fund32"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2017/23920-9</award-id><principal-award-recipient><name><surname>Knittel</surname><given-names>Thiago L</given-names></name></principal-award-recipient></award-group><award-group id="fund33"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2016/24163-4</award-id><principal-award-recipient><name><surname>Knittel</surname><given-names>Thiago L</given-names></name></principal-award-recipient></award-group><award-group id="fund34"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>#2016/23328-0</award-id><principal-award-recipient><name><surname>Knittel</surname><given-names>Thiago L</given-names></name></principal-award-recipient></award-group><award-group id="fund35"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003593</institution-id><institution>Conselho Nacional de Desenvolvimento Científico e Tecnológico</institution></institution-wrap></funding-source><award-id>#310287/2018-9</award-id><principal-award-recipient><name><surname>Mori</surname><given-names>Marcelo A</given-names></name><name><surname>Farias</surname><given-names>Alessandro S</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The infection of T helper lymphocytes by SARS-CoV-2, mediated via the CD4 molecule, alters cellular function and enhances expression of the anti-inflammatory cytokine IL-10, potentially impairing immune response in individuals with COVID-19.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Coronavirus Disease 2019 (COVID-19) has rapidly spread across the globe, being declared a pandemic by the World Health Organization on March 11, 2020. COVID-19 has caused millions of deaths around the world. Most of the deaths are associated with acute pneumonia, cardiovascular complications, and organ failure due to hypoxia, exacerbated inflammatory responses, and widespread cell death (<xref ref-type="bibr" rid="bib7">Candido et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Laing et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Li et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Moore and June, 2020</xref>; <xref ref-type="bibr" rid="bib73">Zhang et al., 2020</xref>). Individuals that progress to the severe stages of COVID-19 manifest marked alterations in the immune response, characterized by reduced overall protein synthesis, cytokine storm, lymphocytopenia, and T cell exhaustion (<xref ref-type="bibr" rid="bib3">Arunachalam et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">De Biasi et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Moore and June, 2020</xref>; <xref ref-type="bibr" rid="bib59">Thoms et al., 2020</xref>). In addition to these acute effects on the immune system, a considerable proportion of infected individuals present low titers of neutralizing antibodies (<xref ref-type="bibr" rid="bib48">Robbiani et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Souza et al., 2021</xref>). Moreover, the levels of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) decay rapidly after recovery in part of the infected individuals (<xref ref-type="bibr" rid="bib37">Long et al., 2020</xref>), suggesting that SARS-CoV-2 infection may exert profound and long-lasting complications to adaptive immunity. Recently, it has been shown that SARS-CoV-2 is able to infect lymphocytes (<xref ref-type="bibr" rid="bib46">Pontelli et al., 2022</xref>; <xref ref-type="bibr" rid="bib54">Shen et al., 2022</xref>). In this context, it is urgent to characterize the replicative capacity and the effects of SARS-CoV-2 replication in different immune cells, especially those involved with the formation of immunological memory and effective adaptive response, such as CD4<sup>+</sup> T lymphocytes.</p><p>In what has been proposed to be the canonical mechanism of SARS-CoV-2 infection, the spike glycoprotein of SARS-CoV-2 (sCoV-2) binds to the host angiotensin-converting enzyme 2 (ACE2), after which it is cleaved by TMPRSS2 (<xref ref-type="bibr" rid="bib25">Hoffmann et al., 2020</xref>). While TMPRSS2 is ubiquitously expressed in human tissues (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), ACE2 is mainly expressed in epithelial and endothelial cells, as well as in the kidney, testis, and small intestine (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Still, a wide variety of cell types are potentially infected by SARS-CoV-2 (<xref ref-type="bibr" rid="bib10">Codo et al., 2020</xref>; <xref ref-type="bibr" rid="bib11">Crunfli et al., 2022</xref>; <xref ref-type="bibr" rid="bib31">Lamers et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">de Oliveira et al., 2022</xref>; <xref ref-type="bibr" rid="bib45">Pascoal et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Saccon et al., 2022</xref>; <xref ref-type="bibr" rid="bib70">Yang et al., 2020</xref>), even though some of these cells express very low levels of ACE2. We showed that this is the case for lymphocytes (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). These findings suggest that either SARS-CoV-2 uses alternative mechanisms to enter these cells or that auxiliary molecules at the plasma membrane may promote infection by stabilizing the virus until it interacts with ACE2. In agreement with the latter, binding of sCoV-2 to certain cell surface proteins facilitates viral entry (<xref ref-type="bibr" rid="bib8">Cantuti-Castelvetri et al., 2020</xref>; <xref ref-type="bibr" rid="bib9">Cecon et al., 2022</xref>).</p><p>Since the structures of the spike of SARS-CoV-1 (sCoV-1) and the sCoV-2 proteins are similar (<xref ref-type="bibr" rid="bib66">Wrapp et al., 2020</xref>; <xref ref-type="bibr" rid="bib71">Yuan et al., 2020</xref>), we used the P-HIPSTer algorithm to uncover human proteins that putatively interact with spike (<xref ref-type="bibr" rid="bib32">Lasso et al., 2019</xref>). Seventy-one human proteins were predicted to interact with sCoV-1 (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). We then cross-referenced the proteins with five databases of plasma membrane proteins to identify the ones located on the cell surface (see ‘Methods’ for details). CD4 was the only protein predicted to interact with sCoV-1 that appeared in all five databases (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). CD4 is expressed mainly in T helper lymphocytes and has been shown to be the co-receptor to HIV (<xref ref-type="bibr" rid="bib51">Shaik et al., 2019</xref>). Since CD4<sup>+</sup> T lymphocytes orchestrate innate and adaptive immune response (<xref ref-type="bibr" rid="bib21">Gasteiger and Rudensky, 2014</xref>; <xref ref-type="bibr" rid="bib44">O’Shea and Paul, 2010</xref>), infection of CD4<sup>+</sup> T cells by SARS-CoV-2 could explain lymphocytopenia and dysregulated inflammatory response in severe COVID-19 patients. Moreover, from an evolutionary perspective, infection of CD4<sup>+</sup> T cells represents an effective mechanism for viruses to escape the immune response (<xref ref-type="bibr" rid="bib69">Xu et al., 2001</xref>).</p><p>To test whether human primary T cells are infected by SARS-CoV-2, we purified CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> T cells from the peripheral blood of noninfected healthy controls/donors (HC), incubated these cells with SARS-CoV-2 for 1 hr, and washed them the three times with PBS. The viral load was measured 24 hr post infection. We were able to detect SARS-CoV-2 RNA in CD4<sup>+</sup> T cells, but not CD8<sup>+</sup> T cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A</xref>). To confirm the presence of SARS-CoV-2 in the cells, we performed in situ hybridization using probes against the viral RNA-dependent RNA polymerase (RdRp) gene, immunofluorescence for sCoV-2 using antibodies against spike protein and transmission electron microscopy (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). In parallel, we infected primary CD4<sup>+</sup> T cells with the VSV-mCherry-SARS-CoV-2 pseudotype virus (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B</xref>). All approaches confirmed that SARS-CoV-2 infects CD4<sup>+</sup> T cells. Notably, the amount of SARS-CoV-2 RNA remains roughly stable until 48 hr post infection (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Of note, although most of the data presented here was generated using the ancient SARS-CoV-2 B lineage, CD4<sup>+</sup> T cells were also infected by the P.1 (gamma) variant (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4C</xref>). Furthermore, we identified the presence of the negative strand (antisense) of SARS-CoV-2 in the infected cells (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4D</xref>), demonstrating that the virus replicates in T helper cells. We also found by plaque assay analysis that SARS-CoV-2-infected CD4<sup>+</sup> T cells release infectious viral particles, although much less efficiently than Vero cells (positive control) (<xref ref-type="fig" rid="fig1">Figure 1E</xref> and <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4E</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects CD4<sup>+</sup> T cells in vitro and in vivo.</title><p>Peripheral blood CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> were exposed to mock control or SARS-CoV-2 (CoV-2) (Multiplicity of Infection (MOI) = 1) for 1 hr under continuous agitation. (<bold>A</bold>) Viral load was assessed by RT-qPCR 24 hr after infection. (<bold>B</bold>) Cells were washed, cultured for 24 hr, fixed with 4% paraformaldehyde (PFA), and stained with the RdRp probe for in situ hybridization or anti-sCoV-2 for immunofluorescence. Cells were analyzed by confocal microscopy. (<bold>C, C1–C5</bold>) Representative transmission electron microscopy (EM) micrographs showing viral particles (asterisks) inside lymphocytes 2 hr after infection. (<bold>D</bold>) Viral load was determined by qPCR 2 hr, 6 hr, 12 hr, 24 hr, and 48 hr after infection. (<bold>E</bold>) Vero cells were incubated with the supernatant of mock control or CoV-2-infected CD4<sup>+</sup>T cells under continuous agitation for 1 hr. The viral load in Vero cells was measured after 72 hr using plaque assay. PFU, plaque-forming unit. (<bold>F</bold>) Viral load was measured by RT-qPCR in peripheral blood CD4<sup>+</sup> and CD8<sup>+</sup> T cells from healthy controls (HC) and COVID-19 patients. (<bold>G</bold>) CoV-2 RNA detection in CD4<sup>+</sup> T cells from bronchoalveolar lavage fluid (BALF) single-cell RNA sequencing data revealing the presence of CoV-2 RNA. Data represents mean ± SEM of at least two independent experiments performed in triplicate or duplicate (f). ***p&lt;0.001; ND, not detected.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Comprehensive analysis of <italic>ACE2</italic>, <italic>TMPRSS2</italic>, and <italic>CD4</italic> expression in human tissues and cell types.</title><p>(<bold>A</bold>) Expression of <italic>ACE2</italic>, <italic>TMPRSS2,</italic> and <italic>CD4</italic> in multiple tissues and cell types according to BioGPS database and The Human Protein Atlas. (<bold>B</bold>) NX expression denotes consensus mRNA expression between multiple databases. (<bold>C</bold>) Protein detection through immunohistochemistry data was plotted based on The Human Protein Atlas annotations (quantity classifications are subjective). Top 25 cells/tissues with the highest expression of <italic>CD4</italic> are marked.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title><italic>ACE2</italic> expression in peripheral blood leukocytes.</title><p>(<bold>A, B</bold>) Flow cytometry analysis of ACE2 in peripheral blood cells (FMO: gray; anti-ACE2: orange): CD3<sup>+</sup>CD4<sup>+</sup>, CD3<sup>+</sup>CD8<sup>+</sup>, CD19<sup>+</sup>, CD123<sup>+</sup>, CD14<sup>+</sup> and CD16<sup>+</sup>. CD14<sup>-</sup>.(<bold>C</bold>) mRNA expression of <italic>ACE2</italic> and <italic>TMPRSS2</italic> in T lymphocytes, A3.01, A2.01, and A2.04 cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Proteomic <italic>in silico</italic> analysis unveils interactions of SARS-CoV-1 with human cellular membrane proteins.</title><p>(<bold>A</bold>) Venn diagram of human proteins that were predicted by P-HIPSTer to interact with sCoV-1 and considered as part of cellular membrane in at least one database. Proteins found in at least two databases are annotated. (<bold>B</bold>) Molecular function enrichment of 71 predicted human proteins that interact with sCoV-1 according to P-HIPSTer.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Evaluation of SARS-CoV-2 infection dynamics in CD4<sup>+</sup> T cells.</title><p>(<bold>A</bold>) Relative expression of the viral envelope (E), nucleocapsid (N), and RNA-dependent RNA polymerase (RdRp) genes in peripheral blood CD4<sup>+</sup> T cells infected with mock control or CoV-2. (<bold>B</bold>) Primary human CD4<sup>+</sup> T cells were incubated with pseudotype (VSV-mCherry-CoV-2). (<bold>C</bold>) Peripheral blood CD3<sup>+</sup>CD4<sup>+</sup> was infected with mock control or SARS-CoV-2 (CoV-2) lineages (<bold>B</bold> and P.1) (MOI 1) for 1 hr under continuous agitation. Viral load was assessed by RT-qPCR 24 hr after infection. (<bold>D</bold>) PCR for the antisense CoV-2 strand was performed in CD4<sup>+</sup> T and Vero (positive control) cells infected with mock or CoV-2. (<bold>E</bold>) Vero cells were incubated with the supernatant of mock control or CoV-2-infected CD4<sup>+</sup> T cells under continuous agitation for 1 hr. The viral load in Vero was measured after 72 hr using plate assay. PFU, plaque-forming units.</p><p><supplementary-material id="fig1s4sdata1"><label>Figure 1—figure supplement 4—source data 1.</label><caption><title>Original agarose gel with PCR for the antisense CoV-2 strand in CD4<sup>+</sup> T and Vero (positive control) cells infected with mock or CoV-2.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84790-fig1-figsupp4-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>Gene signature of individual CD4<sup>+</sup> T cells population.</title><p>CD4<sup>+</sup> T cell subpopulations were annotated considering a high differential expression of <italic>CD4, CCR7, IL7R,</italic> and <italic>IL32</italic> gene markers.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig1-figsupp5-v1.tif"/></fig></fig-group><p>To investigate whether SARS-CoV-2 infects CD4<sup>+</sup> T cells in vivo, we purified CD4<sup>+</sup> and CD8<sup>+</sup> T cells from peripheral blood cells of COVID-19 patients (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Similar to our ex vivo experiments, SARS-CoV-2 RNA was detected in CD4<sup>+</sup> T cells from COVID-19 patients (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Using publicly available single-cell RNA sequencing (scRNAseq) data (<xref ref-type="bibr" rid="bib36">Liao et al., 2020</xref>), we detected the presence of SARS-CoV-2 RNA in 2.1% of CD4<sup>+</sup> T cells of the bronchoalveolar lavage (BAL) of patients with severe COVID-19 (<xref ref-type="fig" rid="fig1">Figure 1F</xref> and <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>). Thus, our data demonstrate that SARS-CoV-2 infects CD4<sup>+</sup> T cells.</p><p>Next, we sought to explore the role of the CD4 molecule in SARS-CoV-2 infection. Based on the putative interaction found using P-HIPSTer, we performed molecular docking analyses and predicted that sCoV-2 receptor binding domain (RBD) directly interacts with the N-terminal domain (NTD) of CD4 Ig-like V type (<xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Molecular dynamics (MD) simulations with stepwise temperature increase were applied to challenge the kinetic stability of the docking model representatives (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Two models remained stable after the third step of simulation at 353 K and represent likely candidates for the interaction between the CD4 NTD and sCoV-2 RBD (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Additionally, we evaluated the dynamic behavior of closely related binding mode models present in the same cluster as these two models. We observed a strong structural convergence toward the putative model in one case, which indicates plausible and rather stable interaction between CD4 NTD and sCoV-2 RBD (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). The interaction region of RBD with CD4 is predicted to overlap with that of human ACE2 (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). The interaction between CD4 and sCoV-2 was confirmed by co-immunoprecipitation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Binding affinity isotherms, obtained by fluorescence anisotropy assay, confirmed the physical high-affinity interaction between RBD and CD4 (Kd = 22 nM) and spike full length and CD4 (Kd = 27 nM). Considering the similar affinities, these results suggest that the interaction interface between sCoV-2 and CD4 occurs at the RBD (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). Consistent with the hypothesis that CD4-sCoV-2 interaction is required for infection, we observed that pre-incubation with soluble CD4 (sCD4) completely blunted viral load in CD4<sup>+</sup> T cells exposed to SARS-CoV-2 (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Together, these data demonstrate that sCoV-2 binds to the CD4 molecule.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Molecular dynamics simulations of the sCoV-2 receptor binding domain (RBD) and CD4 N-terminal domain (NTD) interaction.</title><p>(<bold>A</bold>) Interaction energy (dG separated) versus root-mean-square deviation (RMSD) plot shows a high diversity of binding modes with similar energies. Among the 500 best models, 50 cluster best-ranked representatives (shown as blue crosses) were selected for further evaluation with molecular dynamics simulations. (<bold>B</bold>) RMSD to the initial docked complex as a function of molecular dynamics simulation time over 200 ns and four steps of temperature. At each temperature step, well-behaved models are depicted as colored curves, while divergent candidates are shown as gray curves. Kinetically stable models making reasonable interactions remain close to their initial docked conformation. Only two models remain stable after the third step of 50 ns at 353 K. For both models, resilient contacts throughout simulation are shown in Fig. S5. (<bold>C</bold>) Interaction models of ACE2 and sCoV-2 RBD. The two best candidates according to molecular dynamics simulation, model 95 and model 148, present distinct binding modes. For the first case, interaction occurs mainly in the N-terminal portion of CD4 NTD, while the latter have important contributions to the central part of this domain. (<bold>D</bold>) Full-length model of sCoV-2 and CD4 NTD interaction obtained by alignment of sCoV-2 RBD from model 148 to the sCoV-2 RBD open state from PDB 6vyb EM structure.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Molecular dynamics simulations of the sCoV-2 receptor binding domain (RBD) and CD4 N-terminal domain (NTD) interaction.</title><p>The two closest cluster members to model 95 (<bold>A</bold>) and model 148 (<bold>B</bold>) were subjected to 100 ns molecular dynamics (MD) simulations at 303 K in triplicate. Neighboring models 3 and 43, in the root-mean-square deviation (RMSD) range of ~2.6–3.8 A to the reference model 95, represent closely related binding modes. Similarly, models 2 and 61 are closely related to cluster-representative model 148. The right panels show the RMSD relative to the reference model as a function of trajectory time. Model 61, initially at 3.16 A from its cluster representative (model 148), converged to the structure of model 148 for all runs. This result provides additional evidence that model 148 is a likely candidate for CD4-RBD binding. (<bold>C</bold>) For model 95, three polar contacts are well defined in the interface region: CD4 lysine 29 is hydrogenbonded to sCov2 glutamic acid 484; glycine carbonyl oxygen and amide hydrogen of serine 125 from CD4 make h-bonds to amide hydrogen of glycine 502 and threonine 500 of sCov2, respectively. (<bold>D</bold>) For model 148, two polar contacts are persistent: one hydrogen bond between CD4 aspartic acid 80 and sCov2 tyrosine 505 and a second hydrogen bond between CD4 glutamic acid 92 and sCov2 arginine 408 whose side-chain orientation is also supported by a third residue, sCov2 aspartic acid 405, which completes a three-residue hydrogen bond network. (<bold>E</bold>) MD simulations on both the sCov2 RBD and CD4 monomers at 303 K and 323 K. (<bold>F</bold>) Histogram of maximum backbone RMSD observed over MD trajectories evaluated in the article. Dashed red line shows where the 4 Å is in the whole distribution. RDD, receptor binding domain.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig2-figsupp1-v1.tif"/></fig></fig-group><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Infection of CD4<sup>+</sup> T cells by SARS-CoV-2 is dependent on CD4 and ACE2 molecules.</title><p>(<bold>A</bold>) Recombinant sCoV-2 (with twin-strep-tag) and CD4 were co-incubated and immunoprecipitated with anti-CD4. Complex formation was determined by Affinity blotting using streptavidin-HRP. (<bold>B, C</bold>) Fluorescence anisotropy curves of Spike full length and Spike receptor binding domain (RBD) binding to CD4 labelled protein, presenting dissociation constants (Kd) of 27 ± 3 nM and 22 ± 3 nM, respectively. The CD4 was labeled with FITC by incubation with fluorescein isothiocyanate probe, at molar ratio 3FITC:1protein, 4°C for 3 hr. The probe excess was removed by a desalting column (HiTrap 5 ml, GE) in a buffer containing 137 mM NaCl, 10 mM Na phosphate, 2.7 mM KCl, pH of 7.4. To evaluate binding affinities, serial dilutions of Spike (RBD or full length) were performed, from 4.5 μM to 100 nM, over 20 nM of labeled CD4. The measurements were taken using ClarioStar plate reader (BMG, using polarization filters of 520 nm for emission and of 495 nm for excitation) and data analysis were performed using OriginPro 8.6 software. The Kds were obtained from data fitted to binding curves through the Hill model. (<bold>D</bold>) Cells were exposed to mock control or SARS-CoV-2 (CoV-2) in the presence of vehicle or soluble CD4 (sCD4) in different concentrations (200, 100, or 50 μg/ml) for 1 hr under continuous agitation. Viral load was assessed by RT-qPCR 24 hr after infection. (<bold>E</bold>) Primary human CD4<sup>+</sup> T cells were incubated with IgG control, or monoclonal anti-CD4 (RPA- T4) antibody 18 hr prior to exposure with mock control or CoV-2. Viral load was determined by RT-qPCR 24 hr after infection. (<bold>F</bold>) A2.01 and A3.01 lineages were cultivated with pseudotype virus (VSV-mCherry-CoV-2). Percentage of infected cells and flow cytometry analysis. (<bold>G</bold>) CD4 abundance by western blotting (upper panel) and flow cytometry (lower panel). (<bold>H</bold>) Viral load of CoV-2 in A2.01 and A2.04. (<bold>I</bold>) Peripheral blood CD4<sup>+</sup> T cells were incubated with IgG control or anti-ACE2 (αACE2) polyclonal antibody 18 hr prior to exposure with mock control or CoV-2 for 1 hr. Viral load was determined 24 hr after infection. (<bold>J</bold>) CD4<sup>+</sup> T cells were incubated with vehicle or camostat mesylate for 18 hr before the exposure with mock control or CoV-2 for 1 hr. Viral load was analyzed by RT-qPCR. Data represents mean ± SEM of at least two independent experiments performed in triplicate. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.0001.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Original co-immunoprecipitation blot.</title><p>Recombinant sCoV-2 and CD4 were co-incubated and immunoprecipitated with anti-CD4.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84790-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Original ACE2 abundance by western blotting in T cell lines.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84790-fig3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Original CD4 abundance by western blotting in T cell lines.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84790-fig3-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3—source data 4.</label><caption><title>Original GAPDH abundance by western blotting in T cell lines.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84790-fig3-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Implication of ACE2 and CD4 expression profile for SARS-CoV-2 infection dynamics.</title><p>(<bold>A</bold>) Western blotting of ACE2 and CD4 in Caco-2, A2.01, A3.01 cells, and CD4<sup>+</sup> T lymphocytes. (<bold>B</bold>) Flow cytometry analysis of CD4 (left) and ACE2 (right) expression primary CD4<sup>+</sup> T cells (peripheral blood mononuclear cell [PBMC]), A2.01 and A3.01. (<bold>C</bold>) Temporal viral load of SARS-CoV-2 in A2.01 and A3.01 lineages cells.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Western blotting of ACE2 in Caco-2, A2.01, A3.01, and CD4<sup>+</sup> T lymphocytes.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84790-fig3-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Western blotting of CD4 in Caco-2, A2.01, A3.01, and CD4<sup>+</sup> T lymphocytes.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84790-fig3-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata3"><label>Figure 3—figure supplement 1—source data 3.</label><caption><title>Western blotting of B-actin in Caco-2, A2.01, A3.01, and CD4<sup>+</sup> T lymphocytes.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84790-fig3-figsupp1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig3-figsupp1-v1.tif"/></fig></fig-group><p>To gain further insight into the importance of CD4-sCoV-2 binding to SARS-CoV-2 infection, we purified CD4<sup>+</sup> T cells and preincubated them with a CD4 monoclonal antibody (RPA-T4) (<xref ref-type="bibr" rid="bib44">O’Shea and Paul, 2010</xref>). We observed that CD4 inhibition reduced SARS-CoV-2 load (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Moreover, we used human T cell lines that express CD4 (A3.01) or not (A2.01) (<xref ref-type="bibr" rid="bib19">Folks et al., 1985</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Despite expressing higher levels of ACE2 and TMPRSS2 than primary CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), the presence of CD4 was sufficient to increase viral load in A3.01 cells compared to A2.01 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). These results were confirmed by using the VSV-mCherry-SARS-CoV-2 pseudotype model (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Importantly, the introduction of CD4 in A2.01 increased viral load (<xref ref-type="fig" rid="fig3">Figure 3H and H</xref>).</p><p>Our immunoprecipitation experiments indicated no physical interaction between CD4 and ACE2 (data not shown). Since CD4<sup>+</sup> T cells have very low <italic>ACE2</italic> expression, we tested whether CD4 alone was sufficient to allow SARS-CoV-2 entry. Inhibition of ACE2 using polyclonal antibody (<xref ref-type="fig" rid="fig3">Figure 3I</xref>) diminished SARS-CoV-2 entry in CD4<sup>+</sup> T cells. Moreover, the inhibition of TMPRSS2 with camostat mesylate reduced SARS-CoV-2 load (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Altogether, these data demonstrate that ACE2, TMPRSS2, and CD4 are all required to allow the infection of CD4<sup>+</sup> T cells by SARS-CoV-2.</p><p>To assess the consequences of SARS-CoV-2 infecting CD4<sup>+</sup> T cells, we performed mass spectrometry-based shotgun proteomics in CD4<sup>+</sup> T cells exposed to SARS-CoV-2 ex vivo. We found that SARS-CoV-2 infection alters multiple housekeeping pathways associated with the immune system, infectious diseases, cell cycle, and cellular metabolism (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1 and 2</xref>). SARS-CoV-2 exposure elicits alterations associated with ‘cellular responses to stress,’ which include changes in proteins involved in translation, mitochondrial metabolism, cytoskeleton remodeling, cellular senescence, and apoptosis (<xref ref-type="fig" rid="fig4">Figure 4B</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). In agreement, ex vivo exposure of CD4<sup>+</sup> T cells with SARS-CoV-2 resulted in 10% reduction of cell viability 24 hr after infection with a low MOI (0.1) (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). SARS-CoV-2 may cause cell death by different mechanisms. SARS-CoV-2 can induce apoptosis in different cell lines through stimulation of autophagy via inhibition of mTOR signaling (<xref ref-type="bibr" rid="bib35">Li et al., 2021</xref>). It can also induce inflammasome activation and pyroptosis in primary monocytes and peripheral blood mononuclear cells (PBMCs) from COVID-19 patients (<xref ref-type="bibr" rid="bib2">Alvim et al., 2020</xref>). In epithelial respiratory and kidney cell lines, SARS-CoV drives multimodal necrosis (<xref ref-type="bibr" rid="bib72">Yue et al., 2018</xref>). In lymphocytes, however, it has been demonstrated that apoptosis is the mechanism underlying SARS-CoV-2-mediated cell death (<xref ref-type="bibr" rid="bib11">Crunfli et al., 2022</xref>), which is in line with our proteomic data (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1 and 2</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Infection of CD4<sup>+</sup> T cells by SARS-CoV-2 alters cell function and triggers IL-10 production.</title><p>(<bold>A</bold>) Heatmap of differentially expressed proteins and their associated biological processes. (<bold>B</bold>) Network of differentially expressed proteins and their associated biochemical pathways. (<bold>C</bold>) Relative expression of <italic>IFNγ, IL-17A</italic>, <italic>TGFβ,</italic> and <italic>IL-10</italic> genes in peripheral blood CD3<sup>+</sup> CD4<sup>+</sup> cells from COVID-19 patients (moderate or severe) and healthy control (HC). Data represents mean ± SEM. Each dot representes a patient sample. (<bold>D</bold>) Relative expression of <italic>IL-10</italic> gene in primary CD4<sup>+</sup> T cells infected with SARS-CoV-2. (<bold>E</bold>) Representative immunoblotting of phosphorylated CREB-1Ser133 (pCREB) and total or phosphorylated STAT3 in peripheral blood CD3<sup>+</sup> CD4<sup>+</sup> exposed to mock control or SARS-CoV-2. Phosphorylated ATF-1 is detected by the same antibody used to detect pCREB. ***p&lt;0.001, **p&lt;0.01, *p&lt;0.05.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original immunoblotting of phosphorylated CREB-1Ser133 (pCREB) and phoshorylated ATF-1.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84790-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Original immunoblotting of phosphorylated STAT3.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84790-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Original immunoblotting of total STAT3.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84790-fig4-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>Original immunoblotting of Vinculin.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84790-fig4-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Analysis of differentially expressed proteins and their impact on biological processes.</title><p>(<bold>A</bold>) Foam Tree according to the biological processes affected by the differentially expressed proteins. (<bold>B</bold>) Network of enriched terms colored by cluster ID; nodes that share the same cluster ID are typically close to each other. Bar graph of enriched terms across input gene lists, colored by p-values.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Functional protein network and enrichment analysis in infected CD4<sup>+</sup> T cells.</title><p>(<bold>A</bold>) Functional interaction network of proteins (identified by their gene name). (<bold>B</bold>) Protein interaction (identified by their gene name) of significantly altered proteins in infected CD4<sup>+</sup> T cells with 0.7 confidence score and functional enrichment for top 5 Gene Ontology terms. Node size is related to p-value, and node colors show the direction of expression.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Integrated analysis of BAL CD4<sup>+</sup> T cells shows immune dysregulation in COVID-19 patients.</title><p>(<bold>A</bold>) Flowchart of the of t-SNE-based analysis of human BAL (subclustered of CD4<sup>+</sup> T cells) of healthy, moderate, and severe COVID-19 patients. (<bold>B</bold>) Gene expression of <italic>TGFB1</italic> in counts per million. (<bold>C</bold>) Gene expression of <italic>IL10</italic> in counts per million. (<bold>D</bold>) Gene expression of <italic>IFNG</italic> in counts per million. (<bold>E</bold>) Gene expression of <italic>IL17A</italic> in counts per million. Each dot represents a cell. (<bold>F</bold>) Viability of CD4<sup>+</sup> T cells 24 hr after incubation with mock (blue) or CoV-2 (orange). ***p&lt;0.001, **p&lt;0.01, *p&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-fig4-figsupp3-v1.tif"/></fig></fig-group><p>The expression and release of IL-10 have been widely associated with chronic viral infections and determines viral persistence (<xref ref-type="bibr" rid="bib6">Brooks et al., 2006</xref>). Noteworthy, increased serum levels of IL-10 are associated with COVID-19 severity (<xref ref-type="bibr" rid="bib24">Han et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">Zhao et al., 2020</xref>). We found that IL-10 expression by CD4<sup>+</sup> T cells was higher in BAL (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>) and blood (<xref ref-type="fig" rid="fig4">Figure 4C</xref>) of severe COVID-19 patients. These changes were at least in part cell autonomous since purified CD4<sup>+</sup> T cells exposed to SARS-CoV-2 also expressed higher levels of IL-10 (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Due to the immunomodulatory role of IL-10, we measured the expression of key pro- and anti-inflammatory cytokines involved in the immune response elicited by CD4<sup>+</sup> T cells. CD4<sup>+</sup> T cells from severe COVID-19 patients had decreased expression of IFNγ and IL-17A in relation to cells from patients with the moderate form of the disease or healthy donors (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). These results show that SARS-CoV-2 induces IL-10 expression in CD4<sup>+</sup> T cells, which is associated with suppression of genes that encode key pro-inflammatory cytokines, such as IFNγ and IL-17A, and correlates with disease severity.</p><p>The activation of the transcription factor CREB-1 via Ser<sup>133</sup> phosphorylation induces IL-10 expression (<xref ref-type="bibr" rid="bib22">Gee et al., 2006</xref>). Consistent with IL-10 upregulation, CREB-1 phosphorylation at Ser<sup>133</sup> was increased in SARS-CoV-2-infected CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Thus, SARS-CoV-2 infection triggers a signaling cascade that culminates in the upregulation of IL-10 in CD4<sup>+</sup> T cells. Altogether, our data demonstrate that SARS-CoV-2 infects CD4<sup>+</sup> T cells, impairs cell function, leads to increased IL-10 expression, and compromises cell viability, which in turn dampens immunity against the virus and contributes to disease severity.</p><p>Impaired innate and adaptive immunity is a hallmark of COVID-19, particularly in patients that progress to the critical stages of the disease (<xref ref-type="bibr" rid="bib23">Hadjadj et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Mathew et al., 2020</xref>). Here, we propose that the alterations in immune responses associated with severe COVID-19 are at least partially triggered by infection of CD4<sup>+</sup> T helper cells by SARS-CoV-2 and consequent dysregulation of immune function. T helper cells are infected by SARS-CoV-2 using a mechanism that involves binding of sCoV-2 to CD4 and entry mediated by the canonical ACE2/TMPRSS2 pathway. We propose a model where CD4 stabilizes SARS-CoV-2 on the cell membrane until the virus encounters ACE2 to enter the cell. Moreover, Cecon and colleagues showed that CD4 co- expression with ACE2 in HEK293 cells decreases the affinity and the maximal binding between the sCoV-2 RBD and ACE2 (<xref ref-type="bibr" rid="bib9">Cecon et al., 2022</xref>), which is in line with our MD results and the binding assays (<xref ref-type="fig" rid="fig3">Figure 3</xref>), suggesting an intricate mechanism of modulation of SARS- CoV-2 infection in CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Taken together, these data indicate that in CD4-expressing cells direct binding of sCoV-2 to the CD4 molecule represents a potential mechanism to favor viral entry.</p><p>Once in CD4<sup>+</sup> T cells, SARS-CoV-2 leads to protein expression changes consistent with alterations in pathways related to stress response, apoptosis, and cell cycle regulation, which, if sustained, culminate in cell dysfunction and may lead to cell death. SARS-CoV-2 also results in phosphorylation of CREB-1 transcription factor and induction of its target gene IL-10 in a cell-autonomous manner. IL-10 is a powerful anti-inflammatory cytokine and has been previously associated with viral persistence (<xref ref-type="bibr" rid="bib6">Brooks et al., 2006</xref>). Serum levels of IL-10 increase during the early stages of the disease – when viral load reaches its peak – and may predict COVID-19 outcome (<xref ref-type="bibr" rid="bib24">Han et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">Zhao et al., 2020</xref>). This increase occurs only in patients with the severe form of COVID-19 (<xref ref-type="bibr" rid="bib74">Zhao et al., 2020</xref>). In contrast, we found IFNγ and IL-17A to be upregulated in CD4<sup>+</sup> T cells of patients with moderate illness, indicating a protective role for these cytokines. However, in patients with severe illness, the expression of IFNγ and IL-17A in CD4<sup>+</sup> T cells is dampened. IL-10 is a known suppressor of Th1 and Th17 responses and it is likely to contribute to the changes in IFNγ and IL-17A. These features will ultimately reflect in the quality of the immune response, which in combination with T cell death and consequent lymphopenia, may result in transient/acute immunodeficiency and impair adaptive immunity in severe COVID-19 patients (<xref ref-type="bibr" rid="bib3">Arunachalam et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">De Biasi et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Thoms et al., 2020</xref>). Lymphocytopenia is a characteristic feature of severe COVID-19 (<xref ref-type="bibr" rid="bib75">Zheng et al., 2020</xref>). Here, we demonstrated that infected CD4<sup>+</sup> T cells undergo cell death, which may contribute to the development of lymphocytopenia. In addition, cytokines such as IL-1β released by infected monocytes can promote T cell dysfunction (<xref ref-type="bibr" rid="bib10">Codo et al., 2020</xref>). Therefore, the decrease in lymphocyte count may be attributed to both infected T cell death and dysfunctional T cells resulting from inflammatory cytokine storm.</p><p>How long these alterations in T cell function persist in vivo and whether they have long-lasting impacts on adaptive immunity remains to be determined. Hence, avoiding T cell infection by blocking sCoV-2-CD4 interaction and boosting T cell resistance against SARS-CoV-2 might represent complementary therapeutic approaches to preserve immune response integrity and prevent patients from progressing to the severe stages of COVID-19.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Subjects</title><p>The samples from patients diagnosed with COVID-19 were obtained at the Clinical Hospital of the University of Campinas (SP-Brazil). Both COVID-19 patients and healthy subjects included in this work signed a term of consent approved by the University of Campinas Committee for Ethical Research (CAAE: 32078620.4.0000.5404; CAEE: 30227920.9.0000.5404). Human blood samples from severe COVID-19 patients analyzed in this study were obtained from individuals admitted at the Clinics Hospital, University of Campinas, and included in a clinical trial (UTN: U1111-1250-1843). In vitro experiments were performed with buffy coats from healthy blood donors provided by The Hematology and Hemotherapy Center of the University of Campinas (CAAE: 31622420.0.0000.5404).</p></sec><sec id="s2-2"><title>Diagnosis</title><p>Nasopharyngeal swabs or bronchoalveolar lavage fluids (BALFs) were tested for SARS-CoV- 2 by real-time qPCR. The tests were performed in the Laboratory of High-Performance Molecular Diagnostic or Laboratory of Clinical Pathology, all located at the University of Campinas. The samples were aliquoted and extracted manually using the MagMAX Viral/Pathogen Nucleic Acid Isolation Kit (Applied Biosystems). Some RNAs were automatically isolated by MagMAX Express-96 Magnetic Particle Processor (Applied Biosystems) following the manufacturer’s protocol. Real-time qPCRs were performed in duplicates using TaqMan Fast Virus 1-Step Master Mix (Applied Biosystems) for the detection of SarbecoV E-gene with specific primers (10 µM) and probe (5 µM). Primer sequences were: forward-<named-content content-type="sequence">ACAGGTACGTTAATAGTTAATAGCGT</named-content>; reverse-<named-content content-type="sequence">ATATTGCAGCAGTACGCACACA</named-content>, Probe:6FAM-<named-content content-type="sequence">ACACTAGCCATCCTTACTGCGCTTCG</named-content>- QSY. Patients were considered positive for COVID-19 when Ct &lt; 38. qPCRs were performed using the Applied Biosystems 7500 Fast Real-time PCR system.</p></sec><sec id="s2-3"><title>Blood sample collection and lymphocyte separation</title><p>Each COVID-19 patient had heparin and plain blood tubes collected. Whole blood, serum, and plasma samples were separated. PBMCs from COVID-19 patients and buffy coats were obtained through the Histopaque-1077 density gradient (Sigma-Aldrich). Samples were diluted in Hanks (1:1) and gently poured into 15 or 50 ml conical tubes containing 3 or 10 ml of Histopaque, respectively. Then, the samples were centrifuged at 1400 rpm for 30 min at 4°C without brake. The PBMC layer was collected into a new tube, lymphocytes were sorted (see below), and incubated overnight at 37°C with 5% CO<sub>2</sub> atmosphere with RPMI 1640 (Gibco) containing 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin (P/S).</p></sec><sec id="s2-4"><title>A2.01, A2.04, and A3.01 cell lines</title><p>The A3.01 (ARP-166) and A2.01 (ARP-2059) cells were acquired from the NIH AIDS Reagent Program (MD) and maintained in RPMI 1640 (Gibco) containing 10% FBS and 1% P/S at 37°C with 5% CO<sub>2</sub> atmosphere. Mycoplasma contamination was not detected. A3.01 is a lymphoblastic leukemia cell line that expresses high levels of CD4, while A2.01 does not show detectable levels of CD4. The A2.04 was produced for this article. In brief, the coding sequence for CD4 was amplified from pCMV.CD4 and cloned into the BglII/SalI cloning site of pMSCV-IRES-GFP. The retrovirus carrying pMSCV-CD4-IRES-GFP vector was produced in Peak cells by using pVSV-G and pCL-Eco packing vectors as previously described (<xref ref-type="bibr" rid="bib57">Tavares et al., 2016</xref>; <xref ref-type="bibr" rid="bib58">Tavares et al., 2020</xref>). The A2.01 cells (<xref ref-type="bibr" rid="bib20">Folks et al., 1986</xref>) were transduced with this retrovirus and sorted for GFP positive in the BD FACSCanto II flow cytometer in the Ribeirão Preto Center for Cell-Based Therapy/Hemotherapy, and the confirmation for CD4 expression was done by western blot and flow cytometry.</p></sec><sec id="s2-5"><title>Virus and infection</title><p>The ancient SARS-CoV-2 viral lineage [CoV-2(B)] was isolated from the second confirmed case of COVID-19 in Brazil and kindly donated by Prof. Dr. Edson Luiz Durigon (University of São Paulo, Brazil; SARS.CoV-2/SP02.2020, GenBank accession number MT126808). The SARS-CoV-2 gamma variant [CoV-2(P.1)] was isolated from residual nasopharyngeal lavage specimens of a patient from Manaus City, Brazil, who tested positive for SARS-CoV-2 (GISAID accession ID EPI_ISL_1708318). SARS-CoV-2 virus stocks were propagated in Vero cell line CCL-81 (STR profiling authentication method, mycoplasma contamination not detected, origin: ATCC) and supernatant was harvested at 2 dpi. The viral titers were determined by plaque assays on Vero cells. Vero cells were propagated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 1% P/S, and maintained at 37°C in a 5% CO<sub>2</sub> atmosphere. Cells were incubated with the CoV-2(B) or CoV-2(P.1) lineage (MOI = 1 unless indicated otherwise) for 1 hr at room temperature. After viral adsorption, cells were washed three times with PBS and incubated with a culture medium under standard culture conditions (37°C and 5% CO<sub>2</sub> atmosphere). Most of the in vitro experiments were done with 1 million sorted CD3<sup>+</sup>CD4<sup>+</sup> live cells plated over a well of a 48-well plate. For proteomic and immunoblotting experiments, 4 million live CD3<sup>+</sup>CD4<sup>+</sup> cells were used. All experiments with SARS-CoV-2 were done in a biosafety level 3 laboratory (BSL-3) located in the Institute of Biology from the University Campinas.</p></sec><sec id="s2-6"><title>Flow cytometry</title><p>CD4<sup>+</sup> T cells were sorted with FACSJazz or FACS Melody (BD Biosciences) as CD4<sup>+</sup>CD3<sup>+</sup> and, in some experiments, CD8<sup>-</sup>CD3<sup>+</sup>. CD8<sup>+</sup> T cells were sorted as CD8<sup>+</sup>CD3<sup>+</sup> or CD4<sup>+</sup>CD3<sup>+</sup> (see the list of antibodies in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). We performed flow cytometry with a lineage marker, Lin CD3, CD14, CD16, CD19, CD20 and CD56 to avoid contaminations. Sorted cells were incubated overnight in RPMI 1640 media containing 10% FBS and 1% P/S at 37°C with 5% CO<sub>2</sub> atmosphere for infection. All flow cytometry analyses were performed in FACS Symphony A5 (BD Biosciences). All antibodies used in the present study were sodium azide free.</p></sec><sec id="s2-7"><title>Biotinylated DNA probe synthesis</title><p>Probe synthesis is based on two PCR steps both using the same pair of primers (primer sense: <named-content content-type="sequence">AACACGCAAATTAATGCCTGTCTG;</named-content> primer antisense: <named-content content-type="sequence">GTAACAGCATCAGGTGAAGAAACA</named-content>) for the RdRp gene. The first amplifying PCR mix contains 1× buffer, 1.5 mM MgCl<sub>2</sub>, 0.2 mM dNTP, 0.1 µM of each primer, 1 µl of cDNA (1:10), and 1.5 U Taq polymerase (GoTaq DNA Polymerase, Promega) in a final volume of 50 µl. The reaction was subjected to 35 cycles of PCR including denaturation at 95°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 30 s, following incubation at 72°C for 5 min. PCR samples were analyzed by electrophoresis on a 1% agarose gel in order to verify a final amplicon of 300 pb. The second PCR contained slight modifications in relation to the first, that is, we used 0.2 mM of d (C, G, A) TP and 0.2 µM of 16-dUTP instead of the regular dNTP mix, and used 1 µl of the previous PCR as a template (<xref ref-type="bibr" rid="bib13">Day et al., 1990</xref>).</p></sec><sec id="s2-8"><title>Plaque assays</title><p>Vero cells were grown in 24-well plates up to 80% confluency. Supernatant samples from infected lymphocytes were added and incubated at 37°C with 5% CO<sub>2</sub> for an hour for virus adsorption. Samples were replaced with a semi-solid overlay medium (1% w/v carboxy methyl cellulose in complete DMEM) and incubated at 37°C with 5% of CO<sub>2</sub> for 3–4 d. Plates were fixed in 10% w/v paraformaldehyde (PFA), stained in 1% w/v methylene blue, and results were expressed as viral plaque-forming units per milliliter of sample (PFU/ml).</p></sec><sec id="s2-9"><title>Co-immunoprecipitation</title><p>Co-immunoprecipitation was performed using Pierce protein A/G magnetics beads (Cat# 88803, Thermo Fisher Scientific) immobilized with anti-CD4 antibody (Cat# IM0566, Rhea Biotech). Briefly, 100 µg of magnetic bead was washed in PBS containing 0.05% Tween-20 and then incubated with 10 µg anti-CD4 antibody for 2 hr at 4°C with mixing. For complex formation, we co-incubated 60 pmoles of recombinant CD4 (Cat# 10400-H08H, Sino Biological) and 60 pmoles of Spike S1 Twin-Strep-Tag recombinant protein expressed and generously provided by Dr. Leda Castilho from the Federal University of Rio de Janeiro (<xref ref-type="bibr" rid="bib2">Alvim et al., 2020</xref>). Incubation was performed in 300 μl of PBS and kept overnight at 4°C with gentle agitation. After incubation, the recombinant protein solution was transferred to a 1.5 ml tube with the washed immobilized beads and incubated for 1 hr at room temperature. The complex was precipitated and proteins that did not bind to the beads were subsequently removed during the washes. The protein was eluted from the bead using Laemmli buffer and heat (95° for 5 min). The sample was analyzed by affinity blot using a streptavidin-HRP detection (Cat# 405210, BioLegend). Full-range Rainbow (Cat# RPN800E) was used as the molecular weight marker.</p></sec><sec id="s2-10"><title>Spike target prediction</title><p>The P-HIPSTER database (<ext-link ext-link-type="uri" xlink:href="http://phipster.org">http://phipster.org</ext-link>; last accessed: June 1, 2020) was used to find potential SARS-CoV-2 spike-human interactions. P-HIPSTER discoveries are predicted using protein similarities of known interactions (<xref ref-type="bibr" rid="bib32">Lasso et al., 2019</xref>). Only interactions with a final likelihood ratio (LR) score ≥100 were used in the analysis. According to the authors, this threshold has a validation rate of 76%. To evaluate whether these proteins were found on the cellular membrane, four databases were used. The Human Protein Atlas (<ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org">https://www.proteinatlas.org</ext-link>; last accessed: June 1, 2020) contains tissue and anatomical protein annotations; 1917 proteins classified as ‘Cell Membrane’ were retrieved. Panther GO is a gene set enrichment analysis tool (Mi H, PANTHER version 14: More genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools); 1504 genes annotated as ‘integral components of plasma membrane’ (GO:0005887) were retrieved. EnrichR (<ext-link ext-link-type="uri" xlink:href="https://amp.pharm.mssm.edu/Enrichr/">https://amp.pharm.mssm.edu/Enrichr/</ext-link> ;last accessed: June 1, 2020) is a web-based app that integrates various enrichment analysis tools (<xref ref-type="bibr" rid="bib29">Kuleshov et al., 2016</xref>), which library was used to retrieve JENSEN compartment annotations (<ext-link ext-link-type="uri" xlink:href="https://compartments.jensenlab.org/">https://compartments.jensenlab.org/</ext-link>; last accessed: June 1, 2020) for ‘external side of plasma membrane’ (212), ‘plasma membrane’ (1148), and ‘cell surface’ (715). To find common elements between the datasets and generate the Venn diagram, jvenn (<ext-link ext-link-type="uri" xlink:href="http://jvenn.toulouse.inra.fr/app/">http://jvenn.toulouse.inra.fr/app/</ext-link>; last accessed: June 1, 2020) was used (<xref ref-type="bibr" rid="bib4">Bardou et al., 2014</xref>).</p></sec><sec id="s2-11"><title>Gene set enrichment analysis</title><p>EnrichR was used for enrichment analysis for SARS-CoV-2 spike protein predicted interactions. GO Molecular Function data was downloaded, and enrichments with an adjusted p-value&lt;0.05 were retrieved.</p></sec><sec id="s2-12"><title>Global expression analysis of ACE2, TMPRSS2, and CD4</title><p>To evaluate which tissues and cells express ACE2, TMPRSS2, and CD4, expression data (both protein and consensus mRNA expression, NX) from The Human Protein Atlas (<ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org">https://www.proteinatlas.org</ext-link>; last accessed: July 7, 2020) (<xref ref-type="bibr" rid="bib60">Thul and Lindskog, 2018</xref>) and microarray expression from BioGPS (<ext-link ext-link-type="uri" xlink:href="http://biogps.org/#goto=welcome">http://biogps.org/#goto=welcome</ext-link>; last accessed: Jul 7, 2020) (<xref ref-type="bibr" rid="bib68">Wu et al., 2016</xref>) were downloaded and plotted. In The Human Protein Atlas data, only normalized expression level ≥1 and protein detection ≥ ‘low’ of at least one of the three genes was plotted. In the BioGPS data, this threshold was ≥10 a.u. (arbitrary units).</p></sec><sec id="s2-13"><title>sCoV-2-ACE2-interacting peptide (βACE2) design and synthesis</title><p>A peptide representing the interacting region of SARS-CoV-2 Spike protein with ACE2 and present at the receptor binding domain (RBD receptor binding doming) was designed based on the tridimensional structure described elsewhere (<xref ref-type="bibr" rid="bib52">Shang et al., 2020</xref>). Based on the structure, we selected an unstructured and continuous segment of 16 amino acid residues (THR487-GLY502), which contained most of the interaction points with ACE2. We added to the segment a substitution of CYS488 to SER, which intended to avoid random disulfide bond formation and structural alterations, keeping the same hydrophilicity in the interacting region. An amidated CYS residue was added at the C-terminal of the peptide to allow simple and specific conjugation with accessory detection molecules. The complete 17 amino acid residues (487NCYFPLQSYGFQPTNG502C) were synthesized using standard FMOC solid-phase peptide synthesis chemistry as previously described (<xref ref-type="bibr" rid="bib18">Fields and Noble, 1990</xref>) at a 100 µM scale using RINK-amide resin 0.7 mmol/g (Advanced ChemTech, Cat# SA5130). All FMOC-aas (Advanced ChemTech) were used with 2.5 excess. FMOC-aa coupling reaction assisted by six cycles of 2 min in a home-made microwave device. At the end of coupling reactions, the peptide was cleaved from the resin using a solution of 88% trifluoroacetic acid solution, 4% water, 4% triisopropylsilane, 2% anisole + 30 mg dithiothreitol for 2 hr. Cleaved peptide was precipitated with ethylbutylether and then purified on C18 seppack solid phase extraction cartridges (10 mg, Sigma-Aldrich) using a water:acetonitrile solvent system.</p></sec><sec id="s2-14"><title>Proteomic analysis</title><p>Infected and mock cells were resuspended in RIPA buffer (150 mM NaCl, 1 mM EDTA, 100 mM Tris-HCl, 1% Triton X-100) with freshly added protease and phosphatase inhibitors (Protease Inhibitor Cocktail, Sigma). After three cycles of 30 s of ultra-sonication for cell lysis, the protein amount was quantified by the Pierce BCA protein assay kit (Thermo Scientific).</p><p>Aiming to obtain a higher yield, we performed the FASP protocol for subsequent analyses (<xref ref-type="bibr" rid="bib16">Distler et al., 2016</xref>). The FASP protocol is a method that allows to concentrate proteins and clean up the samples through washing steps in a microcolumn tip with a 10 kDa MW cut off and perform the tryptic digestion in this column. Also, 10 μg of protein were used to carry out the FASP protocol, where the samples were reduced, alkylated, and later digested using trypsin. An amount of 100 fmol/μl of digestion products of Enolase from <italic>Saccharomyces cerevisiae</italic> was added to each sample as internal standard, then separation of tryptic peptides was performed on an ACQUITY MClass System (Waters Corporation). Then, 1 µg of each digested samples was loaded onto a Symmetry C18 5 μm, 180 μm × 20 mm precolumn (Waters Corporation) and subsequently separated by a 120 min reversed phase gradient at 300 nl/min (linear gradient, 2–85% CH<sub>3</sub>CN over 90 min) using a HSS T3 C18 1.8 μm, 75 μm × 150 mm nanoscale LC column (Waters Corporation) maintained at 40°C. After peptide separation, the ionized peptides were acquired by a Synapt G2-Si (Waters Corporation). Differential protein expression was evaluated with data-independent acquisition (DIA) of shotgun proteomics analysis by Expression configuration mode using the Ion Mobility cell (HDMSe). All spectra have been acquired in Ion Mobility Mode by applying a wave velocity for the ion separation of 800 m/s and a transfer wave velocity of 175 m/s. The mass spectrometer operated in ‘Expression Mode,’ switching between low (4 eV) and high (25–60 eV) collision energies on the gas cell, using a scan time of 0.5 s per function over 50–2000 m/z. The processing through low and elevated energy, added to the data of the reference lock mass ([Glu1]-Fibrinopeptide B Standard, Waters Corporation) provides a time-aligned inventory of accurate mass-retention time components for both low and elevated-energy (exact mass retention time [EMRT]).</p><p>Each sample was analyzed in four technical replicates. Continuum LC-MS data from three replicate experiments for each sample was processed for qualitative and quantitative analysis using the software Progenesis QC for Proteomics (PLGS, Waters Corporation). The qualitative identification of proteins was obtained by searching in the <italic>Homo sapiens</italic> database (UniProtKB/Swiss-Prot Protein reviewed 2020). The expression analysis was performed considering technical replicates available for each experimental condition following the hypothesis that each group is an independent variable. Protein identifications were based on the detection of more than two fragment ions per peptide, and more than two peptides measured per protein. The list of normalized proteins was screened according to the following criteria: protein identified in at least 70% of the runs from the same sample and only modulated proteins with a p&lt;0.05 were considered significant. Raw data are available in ProteomeXchange database under accession number PXD020967 (username: reviewer07826@ebi.ac.uk; password: q3qYRlYQ).</p></sec><sec id="s2-15"><title>In situ hybridization</title><p>Sorted CD4<sup>+</sup> T cells were incubated for 24 hr with the SARS-CoV-2 virus (MOI of 1) or mock. After 24 hr, the cells were washed three times with PBS and fixed with 4% PFA for 15 min, at room temperature, followed by two washes with PBS (pH 7.4) prepared with diethylpyrocarbonate (DEPC)-treated water. Further, the cells were seeded on silanized glass slides and kept on a prewarmed surface until liquid is fully evaporated. The slides were washed with PBS and pretreated with 2% H<sub>2</sub>O<sub>2</sub> in methanol for 30 min to bleach auto- and avoid nonspecific fluorescence. They were then washed twice with PBS 0.05% Triton X-100 (PBST), treated with Proteinase K (10 µg/ml) for 2 min, followed by PBST-Glycin (2 mg/ml) for 10 min, and a second fixation step with PFA 4% for 10 min, followed by three more washes with PBST at room temperature. Each sample was pre-hybridized with hybridization solution (Hyb) (50% formamide, 10% dextran sulfate, 2× saline-sodium citrate buffer [SSC] pH 7.0, and 100 µg salmon DNA), without the probe, for at least 2 hr at 37°C in a humid box. Samples were then incubated with Hyb containing the biotinylated probe (100 µl of the probe in 500 µl of Hyb), pre-denaturated (85°C for 10 min), in a humid box overnight at 37°C. The slides were then subjected to sequential washes with 50% Hyb in 2× SSC and 25% Hyb in 2× SSC, for 20 min at 37°C each, and two washes for 10 min each with 2× SSC, 0.2× SSC, and PBS. All samples were incubated with fluorescent streptavidin (Streptavidin, DyLight 594 Conjugated, Thermo Scientific, #21842, 1:300) for 2 hr at room temperature in the humid box protected from light. The slides were washed with PBST, incubated with DAPI (Santa Cruz Biotechnology, SC-3598), diluted 1:1000 in PBST for 5 min at room temperature, protected from light, and mounted in an aqueous mounting solution for confocal imaging.</p></sec><sec id="s2-16"><title>Detection of SARS-CoV-2 antisense strand</title><p>cDNA was generated using SuperScript III First-Strand Synthesis SuperMix (Thermo Fisher) according to the manufacturer’s instructions. Then, 60 ng of RNA were incubated at 65°C for 5 min with 1× annealing buffer and 250 nM of a primer complementary to the anti-sense CoV-2 strand containing a nonviral tag at the 5′ end. The sample was chilled at 4°C for 1 min and incubated at 55°C for 50 min with SuperScript III/RNaseOUT and 1× master mix for reverse transcription (RT). The sample was heated to 85°C for enzyme inactivation. The antisense strand was amplified in a PCR using 100 nM of primers complementary to the nonviral tag and to the antisense CoV-2 strand. As a control for false-priming (<xref ref-type="bibr" rid="bib5">Bessaud et al., 2008</xref>), we performed the RT without the tagged reverse primer and a PCR using both the RT and the PCR primers at 100 nM. The sense strand was also amplified as a control with the same method using nontagged primers for the RT and PCR. The samples were loaded in a 4% agarose gel in Tris/borate/EDTA buffer containing 1× SybrSafe (Thermo Fisher).</p></sec><sec id="s2-17"><title>Immunoblotting</title><p>Cells were infected for 3 hr with the SARS-CoV-2 virus (MOI of 1) or mock, washed with PBS, and the protein was extracted using lysis buffer (Tris-HCl 100 mM pH 7.5; EDTA 1 mM; NaCl 150 mM; 1% Triton X-100; 1× protease and phosphatase inhibitors). Protein quantification was performed using Pierce BCA protein assay kit (Thermo Fisher Scientific). Then, 5 µg protein of each sample was diluted with Laemmli buffer and heated at 95°C during 5 min. Samples were subjected to 10% SDS-PAGE and transferred to PVDF membrane (Cat# 1620177, Bio-Rad). Membranes were blocked with StartingBlock (37539, Thermo Fisher Scientific) for 30 min, and incubated overnight with anti-phospho-CREB (Cat# 9198, Cell Signaling, dilution 1:1000), anti-phospho-STAT3 (Cat# 8059, Santa Cruz, dilution 1:250), anti-STAT3 (Cat# 4904, Cell Signaling, dilution 1:1000), anti-ACE-2 (Cat# ab15348, Abcam, dilution 1:2000), or anti-CD4 (Cat# sc-7219, Santa Cruz, dilution 1:2000). Membranes were washed and incubated during 1 hr with rabbit IgG horseradish peroxidase-conjugated secondary antibodies (Cat# RPN4301, GE Healthcare, diluted 1:10,000 in block buffer). Membranes were then washed and incubated with Immobilon Western Chemiluminescent HRP Substrate (Cat# WBKLS0500, Millipore), and the images were acquired in ChemiDoc Gel Imaging System (Bio-Rad). Anti-Vinculin (Cat#, ab91459, Abcam, dilution 1:1000), anti-actin-beta (Cat#, sc-47778, Santa Cruz, dilution 1:4000), and anti-GAPDH (Cat# G9545, Sigma-Aldrich, dilution 1:5000) antibodies were used as loading controls. Quantification was performed using ImageJ.</p></sec><sec id="s2-18"><title>Immunofluorescence</title><p>Cells were prepared onto silanized glass slides as previously described for in situ hybridization (<xref ref-type="bibr" rid="bib1">Alamri et al., 2017</xref>), followed by a washing step using PBST 0.1 M pH 7.4. To avoid autofluorescence, the cells were treated with 2% H<sub>2</sub>O<sub>2</sub> in methanol for 30 min, washed with PBST, and treated with 0.1 M glycine in PBST for 10 min at room temperature. The samples were then washed and treated with 1% bovine serum albumin (BSA) solution in PBST for 30 min (according to the manufacturer’s suggestion), to block nonspecific epitopes. Cells were incubated with SARS-CoV-2 Spike S1 Antibody (HC2001) (GenScript, A02038) diluted 1:100 in 1% BSA solution in PBST, and incubated overnight at 4°C in a humid box. The slides were then washed and incubated with anti-human IgG Alexa 488 (Thermo Fisher, A11013) diluted 1:500 in 1% BSA solution in PBST for 2 hr at room temperature in a humid box, protected from light. The samples were washed again, incubated with DAPI (Santa Cruz Biotechnology, SC-3598) diluted 1:1000 in 1% BSA solution in PBST for 5 min at room temperature protected from light, and mounted in an aqueous mounting solution for confocal imaging. Microscopy images were acquired with a Zeiss LSM880 with Airyscan on an Axio Observer 7 inverted microscope (Carl Zeiss AG, Germany) with a C Plan-Apochromat ×63/1.4 Oil DIC objective, 4× optical zoom. Prior to image analysis, raw .czi files were automatically processed into deconvoluted Airyscan images using the Zen Black 2.3 software. For DAPI, conventional confocal images were acquired using a 405 nm laser line for excitation and a pinhole set to 1 AU.</p></sec><sec id="s2-19"><title>Transmission electron microscopy</title><p>T lymphocyte cell cultures were pelleted by centrifugation at 500 × <italic>g</italic> for 10 min. Cell culture supernatant was removed and cells were resuspended in 100 µl of the fixative solution, which consisted of 1 M sodium cacodylate aqueous solution supplemented with 2.5 % v/v glutaraldehyde and 3 mM calcium chloride at pH 7.2, and kept overnight (16 hr) at 4°C. Cells were pelleted (1500 rpm for 2 min) and washed in cacodylate buffer with calcium chloride for a total of five times. Post-fixation was performed with 1% reduced osmium tetroxide plus 0.8% potassium ferrocyanide in a cacodylate buffer with calcium chloride for 2 hr at 4°C covered from light. Pellet was recovered by centrifugation at 1500 rpm at 4°C and washed three times in ddH<sub>2</sub>O for 2 min. Cells were resuspended in 4% low melting agarose (approximately 50°C) and centrifuged at 1500 rpm for 10 min at 30°C and kept 20 min on ice for solidification. Agarose pellets were trimmed in small blocks and stained for contrast enhancement with 2% aqueous uranyl acetate overnight at 4°C. Later, samples were washed in ddH<sub>2</sub>O and dehydrated in increasing concentrations of ethanol (20, 50, 70, 80, 90, 100% twice), 1:1 ethanol:acetone, and acetone (twice), 20 min each. Samples were embedded in Embed-812 (Electron Microscopy Science, USA, #14120) following manufacturer’s recommendations. Ultrathin sections (70 nm) were mounted in 200 mesh copper grids and stained with 2% aqueous uranyl acetate and Reynold’s lead citrate. Finished grids were imaged in a JEOL JEM-1400 Transmission Electron Microscope (120 kV accelerating voltage) and/or Helios Nanolab Dualbeam 660 Scanning Transmission Electron Microscope (30 kV accelerating voltage) at the Electron Microscopy Laboratory, Brazilian Nanotechnology National Laboratory, LNNano, CNPEM.</p></sec><sec id="s2-20"><title>RNA extraction cDNA synthesis</title><p>Total RNA was extracted from samples using TRI Reagent (Sigma) (200 µl per pellet of cells) according to the manufacturer’s instructions and quantified using NanoDrop 200 Spectrophotometer (Thermo Scientific). cDNA was synthesized using 500 ng of total RNA and the GoScript Reverse Transcriptase Kit (Promega) or the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) following the manufacturer’s instructions. The cDNA final concentration was 25 ng/μl.</p></sec><sec id="s2-21"><title>qPCR</title><p>Real-time PCR (qPCR) was performed using QuantiNova SYBR Green PCR Kit (QIAGEN) with specific primers (<italic>HPRT</italic> – forward: <named-content content-type="sequence">GACCAGTCAACAGGGGACAT</named-content>, reverse: <named-content content-type="sequence">AACACTTCGTGGGGTCCTTTTC</named-content>; <italic>IL10</italic> – forward: <named-content content-type="sequence">GCCTAACATGCTTCGAGATC</named-content>; reverse: <named-content content-type="sequence">CTCATGGCTTTGTAGATGCC</named-content>; <italic>TGFB1</italic> – forward: <named-content content-type="sequence">AAGTTGGCATGGTAGCCCTT</named-content>, reverse: <named-content content-type="sequence">GCCCTGGATACCAACTATTGC</named-content>; <italic>IFNG</italic> – forward: <named-content content-type="sequence">TTTAATGCAGGTCATTCAGATGTA</named-content>, reverse: <named-content content-type="sequence">CACTTGGATGAGTTCATGTATTGC;</named-content> and <italic>IL17A</italic> – forward: <named-content content-type="sequence">TCCCACGAAATCCAGGATGC</named-content>, reverse: <named-content content-type="sequence">TGTTCAGGTTGACCATCACAGT)</named-content>. Expression levels of each gene were normalized to a housekeeping gene (i.e., hypoxanthine phosphoribosyltransferase 1 [<italic>HPRT1</italic>]). qPCR reaction was performed using 15 ng of cDNA, 300 nM of specific primers, and QuantiNova SYBR Green (QIAGEN). Amplification occurred upon cycling conditions: 95°C for 3 min and 45 cycles of 95°C for 15 s, 60°C for 20 s, and 72°C for 30 s. Amplification plots, melting curves, and Ct values were obtained using CFX Manager (Bio-Rad). Gene expression fold change was calculated with the ΔΔCt method (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). Viral load was determined using specific SARS-CoV-2 N1 primers, as described previously (<xref ref-type="bibr" rid="bib64">Won et al., 2020</xref>) and using qPCRBIO Probe 1-Step Go Lo-Rox (PCR Biosystem) with specific SarbecoV E-gene primers and probe. For the preparation of a standard curve, serial dilutions of SARS-CoV-2 were used. qPCR was performed using the Bio-Rad CFX384 Touch Real-Time PCR Detection System and Thermo Fisher QuantStudio 3. Relative expression of the viral envelope (E), nucleocapsid (N), and RNA-dependent RNA polymerase (RdRp) genes from in vitro CD3<sup>+</sup>CD4<sup>+</sup> cells were detected using GeneFinder COVID-19 Plus Real<italic>Amp</italic>Kit (OSANG Healthcare Co). Expression level of each gene was normalized to internal control of the kit and relative gene expression was calculated as 2<sup>- ΔCT</sup>. For this kit, the qPCR was performed using the Applied Biosystems 7500 Fast Real-time PCR system.</p></sec><sec id="s2-22"><title>Single-cell mRNA sequencing (scRNAseq)</title><p>We reanalyzed the scRNAseq data from six samples of BALF-containing immune cells of severe COVID-19 patients (C145, C146, C148, C149, and C152) by downloading the respective single-cell processed data matrices from GEO under the accession number GSE145926. The number of viral transcripts mapped to SARS-CoV-2 was previously integrated by their authors as an additional feature into data matrices called ‘NcoV’ used to quantify the viral load of SARS-CoV-2. The data matrices were then imported to R version 3.6.3 and analyzed using Seurat v3.1 (<xref ref-type="bibr" rid="bib56">Stuart et al., 2019</xref>).</p><p>A quality control filtering was applied to remove low-quality cells considering a gene number between 200 and 6000, unique molecular identifier (UMI) count &gt; 1000, and mitochondrial gene percentage &lt;0.1. After the filtering step, a total of 37,197 cells and 25,722 features (including SARS-CoV-2 viral load) were left for downstream analysis. The filtered gene-barcode matrix of all samples was integrated with FindIntegrationAnchors and IntegrateData functions considering the first 50 dimensions of canonical correlation analysis (CCA). Then, the filtered data matrix was normalized using the ‘LogNormalize’ method in Seurat with a scale factor of 10,000. The top 3000 variable genes were then identified using the ‘vst’ method in Seurat using the FindVariableFeatures function. Variables ‘nCount_RNA’ and ‘percent.mito’ were regressed out in the scaling step, and principal component analysis was performed using the top 3000 variable genes using 100 dimensions. Then, Uniform Manifold Approximation and Projection and t-Distributed Stochastic Neighbor Embedding were performed on the top 40 principal components for visualizing the cells. Additionally, a clustering analysis was performed on the first 40 principal components using a resolution of 0.8. Then, differential gene expression analysis was performed with the Wilcoxon rank-sum test using the FindAllMarkers function to obtain a list of representative gene markers for each cluster of cells. Representative gene markers were considered based on adjusted p-value&lt;0.05 and average log fold change &gt; 0.25 among cells. T cell cluster annotation was performed using an evidence-based score approach with scCATCH (<xref ref-type="bibr" rid="bib53">Shao et al., 2020</xref>) based on differential gene markers list. Finally, CD4<sup>+</sup> T cell subpopulations were annotated considering a high differential expression of CD4, CCR7, and IL32 gene markers (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>). Based on the methodology applied above, a total of 1846 single cells were identified as CD4<sup>+</sup> T cells. T cells were considered infected assuming a threshold with at least 10% of viral RNA expression. The applied threshold resulted in 39 single cells infected with SARS-CoV-2.</p></sec><sec id="s2-23"><title>Docking</title><p>The RosettaDock4.0 protein docking protocol (<xref ref-type="bibr" rid="bib33">Leman et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Marze et al., 2018</xref>) was applied to model the interaction between CD4 NTD (<xref ref-type="bibr" rid="bib67">Wu et al., 1997</xref>) (PDB ID 1wio, residues 1–178) and sCov2 RBD (<xref ref-type="bibr" rid="bib62">Wang et al., 2020</xref>) (PDB ID 6lzg, residues 333–527) as described previously. Briefly, the first step consisted of generating an ensemble of 100 conformers for each target. The two-stage automated Rosetta docking protocol simulates the physical encounter of the proteins and maximizes interactions, which may lead to binding. In the first stage (global docking), a rigid-body translation-rotation of one of the protein samples’ possible interaction modes using a low-resolution, centroid-based representation of the side chains. RosettaDock4.0 also mimics binding-induced conformational adaptations by assessing a pre-generated list of conformers. This is an important feature for cases where backbone perturbation is inherent to the interface of interaction. Additionally, a score term named Motif Dock Score ranks low-resolution models according to their chance to generate promising high-resolution models, reducing the number of candidates to proceed to the next stage. In the second stage (local docking), the centroid mode is converted into full-atom representation, where small random rigid-body perturbations take place, followed by side-chain relaxation that aims to optimize local interactions. A first set of models consisted of generating 10,000 low-resolution candidates using global docking with 3 Å translation and 8° rotation perturbation parameters. The 2000 highest-ranked models according to Motif Dock Score proceeded to the local docking stage using default parameters (0.1 Å translation and 3° rotation perturbation parameters). Twenty-five high-resolution candidates were generated for each low-resolution input model totaling 50,000 models. A second set of models was generated by first randomizing CD4 NTD orientation previously to docking run. For this strategy, 40,000 low-resolution and 300,000 high-resolution models were generated similarly to the description above. As an alternative docking approach, monomeric chains were also docked using the HADDOCK 2.4 server (<xref ref-type="bibr" rid="bib61">van Zundert et al., 2016</xref>), which returned 40 model candidates spread into 13 clusters. A total of 800 additional models were generated using these models as input to the high-resolution docking stage at RosettaDock4.0. Next, best-ranked 2000 models according to interface score (I_sc) were fully relaxed with Relax application (beta_genpot score function, Rosetta Package) and evaluated with InterfaceAnalyzer application (Rosetta package) to extract interface metrics. A total of 500 top-ranked models according to interface binding energy (dG_separated) were evaluated for pairwise structural similarity with LovoAlign (<xref ref-type="bibr" rid="bib40">Martínez et al., 2007</xref>) and were clustered at 2.0 Å radius. Best-ranked models of each of the first 50 clusters were selected for MD simulation. This set of models is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/ajrferrari/CD4-RBD-interaction-models">https://github.com/ajrferrari/CD4-RBD-interaction-models</ext-link> (copy archived at <xref ref-type="bibr" rid="bib17">Ferrari, 2023</xref>).</p></sec><sec id="s2-24"><title>Molecular dynamics simulations</title><p>MD simulations have been used to discriminate among protein complexes decoys by challenging their thermal stability (<xref ref-type="bibr" rid="bib47">Radom et al., 2018</xref>). All-atom MD simulations were carried out with pmemd within AMBER20 software suite for 50 representative models of CD4 NTD sCov2 RBD interaction obtained as described above. Glycosylation at sCov2 RBD N343 residue (<xref ref-type="bibr" rid="bib63">Watanabe et al., 2020</xref>; <xref ref-type="bibr" rid="bib65">Woo et al., 2020</xref>) was built using the Glycam web server. Each system was solvated in a periodic octahedral water box such that the initial structure was more than 24 Å of its closest image. Neutralizing ions (Na<sup>+</sup> and Cl<sup>-</sup>) were added to a final concentration of 0.15 M (<xref ref-type="bibr" rid="bib38">Machado and Pantano, 2020</xref>). The ff14SB force field (<xref ref-type="bibr" rid="bib39">Maier et al., 2015</xref>) was used for modeling proteins, the GLYCAM06 force field (<xref ref-type="bibr" rid="bib28">Kirschner et al., 2008</xref>) for modeling the glycan, and water was described with the TIP3P model (<xref ref-type="bibr" rid="bib27">Jorgensen et al., 1983</xref>). Electrostatic interactions were evaluated using the Particle Mesh Ewald algorithm (<xref ref-type="bibr" rid="bib12">Darden et al., 1998</xref>), nonbonded interactions were truncated at 9 Å, bonds involving hydrogen atoms were constrained at their equilibrium values, and a time step of 2 fs was used for the numerical integration of the equations of motion. Before production runs, all systems were equilibrated in five sequential steps: (1) 2500 steps of steepest descent line minimization followed by 2500 of conjugate gradient minimization; (2) 1 ns simulation at 303 K in the NVT ensemble with harmonic restraints of 10 kcal mol<sup>–1</sup> Å<sup>–2</sup> to protein and glycan atoms; (3) 1 ns simulation at 303 K in the NPT ensemble with harmonic restraints of 10 kcal mol<sup>–1</sup> Å<sup>–2</sup> to protein and glycan atoms; (4) 1 ns simulation at 303 K in the NPT ensemble with harmonic restraints of 10 kcal mol<sup>–1</sup> Å<sup>–2</sup> to protein backbone atoms; and (5) 1 ns simulation at 303 K in the NPT ensemble without restraints. Subsequently, production runs for assessment of the kinetic stability of the proposed structural models (<xref ref-type="bibr" rid="bib47">Radom et al., 2018</xref>) were performed in the NPT ensemble in four sequential steps: (1) 50 ns simulation at 303 K; (2) 50 ns simulation at 323 K; (3) 50 ns simulation at 353 K; and (4) 50 ns simulation at 383 K. At each production step, models were evaluated according to their root-mean-square deviation (RMSD) to the initial model such that models with RMSD &gt; 4 Å did not proceed to the next step. The 4 Å threshold was rationalized based on the fluctuations observed in the MD simulations on the sCov2 RBD and CD4 monomers independently. These simulations revealed that both monomers exhibited fluctuations ranging between 2 Å and 4 Å when evaluated up to 323 K (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Additionally, for the data contained in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, triplicate production runs were performed for 100 ns at 303 K in the NPT ensemble. All trajectory analyses were performed with CPPTRAJ (<xref ref-type="bibr" rid="bib49">Roe and Cheatham, 2013</xref>). Model structural visualization and image rendering were performed either in PyMOL (The PyMOL Molecular Graphics System, Version Schrödinger, LLC, n.d.) or VMD (<xref ref-type="bibr" rid="bib26">Humphrey et al., 1996</xref>).</p></sec><sec id="s2-25"><title>Fluorescence anisotropy</title><p>Human CD4 (Sino Biological/10400-H08H), ACE2 (GenScript), and purified human thyroid receptor (TR) (negative control) proteins were labeled with FITC by incubation with fluorescein isothiocyanate probe, at molar ratio 3 FITC:1 protein, 4°C for 3 hr. The probe excess was removed by a desalting column (HiTrap 5 ml, GE) in a buffer containing 137 mM NaCl, 10 mM Na phosphate, 2.7 mM KCl, pH of 7.4. To evaluate the affinities between RBD and CD4, TR or ACE2, serial dilutions of RBD (0.01–10 μM) were performed. To evaluate the affinity between Spike full length (LECC/UFRJ LM220720) and CD4, serial dilutions of Spike (0.01–4.5 μM) were performed. The anisotropy curves were assembled in 0three replicates in black 384-well plates (Greiner). After serial dilution setup, each point was incubated with 20 nM of the labeled proteins (CD4, ACE2, or TR) for at least 2 hr at 4°C. For each fluorescence curve, the mixtures were submitted to fluorescence anisotropy measurements using ClarioStar plate reader (BMG, using polarization filters of 520 nm for emission and of 495 nm for excitation). Data analysis was performed using OriginPro 8.6 software, and dissociation constant (Kd) was obtained from data fitted to binding curves through Hill model.</p></sec></sec></body><back><sec sec-type="additional-information" id="s3"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con6"><p>Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con7"><p>Validation, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con10"><p>Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con11"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con13"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con14"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con15"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con16"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con17"><p>Methodology</p></fn><fn fn-type="con" id="con18"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con19"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con20"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con21"><p>Methodology</p></fn><fn fn-type="con" id="con22"><p>Methodology</p></fn><fn fn-type="con" id="con23"><p>Methodology</p></fn><fn fn-type="con" id="con24"><p>Methodology</p></fn><fn fn-type="con" id="con25"><p>Methodology</p></fn><fn fn-type="con" id="con26"><p>Methodology</p></fn><fn fn-type="con" id="con27"><p>Methodology</p></fn><fn fn-type="con" id="con28"><p>Methodology</p></fn><fn fn-type="con" id="con29"><p>Methodology</p></fn><fn fn-type="con" id="con30"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con31"><p>Methodology</p></fn><fn fn-type="con" id="con32"><p>Methodology</p></fn><fn fn-type="con" id="con33"><p>Methodology</p></fn><fn fn-type="con" id="con34"><p>Methodology</p></fn><fn fn-type="con" id="con35"><p>Methodology</p></fn><fn fn-type="con" id="con36"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con37"><p>Methodology</p></fn><fn fn-type="con" id="con38"><p>Methodology</p></fn><fn fn-type="con" id="con39"><p>Methodology</p></fn><fn fn-type="con" id="con40"><p>Methodology</p></fn><fn fn-type="con" id="con41"><p>Methodology</p></fn><fn fn-type="con" id="con42"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con43"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con44"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con45"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con46"><p>Methodology</p></fn><fn fn-type="con" id="con47"><p>Methodology</p></fn><fn fn-type="con" id="con48"><p>Methodology</p></fn><fn fn-type="con" id="con49"><p>Methodology</p></fn><fn fn-type="con" id="con50"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con51"><p>Methodology</p></fn><fn fn-type="con" id="con52"><p>Methodology</p></fn><fn fn-type="con" id="con53"><p>Methodology</p></fn><fn fn-type="con" id="con54"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con55"><p>Methodology</p></fn><fn fn-type="con" id="con56"><p>Methodology</p></fn><fn fn-type="con" id="con57"><p>Methodology</p></fn><fn fn-type="con" id="con58"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con59"><p>Methodology</p></fn><fn fn-type="con" id="con60"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con61"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con62"><p>Resources, Funding acquisition, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con63"><p>Resources, Investigation, Methodology</p></fn><fn fn-type="con" id="con64"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con65"><p>Funding acquisition, Methodology</p></fn><fn fn-type="con" id="con66"><p>Resources, Investigation, Methodology</p></fn><fn fn-type="con" id="con67"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con68"><p>Resources, Data curation, Formal analysis, Funding acquisition, Methodology</p></fn><fn fn-type="con" id="con69"><p>Resources, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con70"><p>Resources, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con71"><p>Resources, Formal analysis, Funding acquisition, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con72"><p>Conceptualization, Resources, Data curation, Formal analysis, Funding acquisition, Writing – original draft</p></fn><fn fn-type="con" id="con73"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con74"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con75"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con76"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The samples from patients diagnosed with COVID-19 were obtained at the Clinical Hospital of the University of Campinas (SP-Brazil). Both COVID-19 patients and healthy subjects included in this work signed a term of consent approved by the University of Campinas Committee for Ethical Research (CAAE: 32078620.4.0000.5404, CAEE: 30227920.9.0000.5404). Human blood samples from severe COVID-19 patients analyzed in this study were obtained from individuals admitted at the Clinics Hospital, University of Campinas and included in a clinical trial (UTN: U1111-1250-1843). Besides, in vitro experiments were performed with buffy coats from healthy blood donors provided by The hematology and hemotherapy Center of the University of Campinas (CAAE: 31622420.0.0000.5404).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s4"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Clinical data about cohorts.</title><p>Gender, age, and admittance oxygen saturation were evaluated.</p></caption><media xlink:href="elife-84790-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Detail results of mass spectrometry-based shotgun proteomics performed in CD4<sup>+</sup> T cells exposed to SARS-CoV-2 ex vivo.</title></caption><media mimetype="application" mime-subtype="xls" xlink:href="elife-84790-supp2-v1.xls"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Information about antibodies used in the article.</title></caption><media xlink:href="elife-84790-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Cycle thresholds (Cts) obtained during qPCR performances in CD4 <sup>+</sup> and CD8 <sup>+</sup> T lymphocytes infection (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) and CD4<sup>+</sup> T cell temporal infection (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</title></caption><media xlink:href="elife-84790-supp4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-84790-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s5"><title>Data availability</title><p>Proteomic raw data are available in ProteomeXchange database under accession number PXD020967, Molecular dynamics dataset is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/ajrferrari/CD4-RBD-interaction-models">https://github.com/ajrferrari/CD4-RBD-interaction-models</ext-link>, copy archived at <xref ref-type="bibr" rid="bib17">Ferrari, 2023</xref>.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Farias</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>SARS-CoV-2 Uses CD4 to Infect T Helper Lymphocytes</data-title><source>PRIDE</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD020967">PXD020967</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Single-cell landscape of bronchoalveolar immune cells in COVID-19 patients</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145926">GSE145926</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We acknowledge the technical support of Elzira E Saviani, Paulo A Baldasso, and Mariana Ozello Baratti. We thank Dr. Leda Castilho (UFRJ) for providing sCoV-2 recombinant protein, Dr. Edson Luiz Durigon (USP) for providing viral strains, and Dr. Hernandes F de Carvalho (UNICAMP) for providing valuable reagents for immunofluorescence. We also thank the National Institute of Science and Technology of Photonics Applied to Cell Biology (INFABIC) for aid with confocal microscopy. We also thank Antonio Borges, Fabiano Montoro, and LNNano/CNPEM for the use of the electron microscopy facility (TEM-C2-26912, TEM-C2-26935). We acknowledge the Spectroscopy and Calorimetry Laboratory of the Brazilian Biosciences National Laboratory (LNBio), CNPEM, Campinas, Brazil, for the support in fluorescence anisotropy assays. This work was supported by grants from FAEPEX-UNICAMP (#2295/20, #2458/20, #2266/20 and #2274/20), São Paulo Research Foundation (FAPESP) (#2021/08354-2, #2019/16116-4, #2019/06372-3, #2020/04583-4, #2013/08293-7, #2020/04579-7, #2015/15626-8, #2018/14933-2, #2020/04746-0, #2019/00098-7, #2020/04919-2, #2017/01184-9, #2019/14465-1, #2020/04558-0, #2016/00194-8), the National Institute of Science and Technology in Neuroimmunomodulation (INCT-NIM) (#465489/2014-1) and FINEP (#01.20.0003.00). ASF and MAM. were supported by CNPq productivity awards (#306248/2017-4 and #310287/2018-9). AJRF, GGD, NSB, LBM, FC, VCC, AB, TLK, GSP, and RGL were supported by FAPESP fellowships (#2019/17007-4, #2016/18031-8, #2019/22398-2, #2019/13552-8, #2019/05155-9, #2019/06459-1, #2019/04726-2, #2017/23920-9, #2016/24163-4, #2016/23328-0). VOB and LNS were supported by FAEPEX fellowship (#2295/20 and #2319/20). DM was supported by CAPES fellowship.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alamri</surname><given-names>A</given-names></name><name><surname>Nam</surname><given-names>JY</given-names></name><name><surname>Blancato</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Fluorescence in situ hybridization of cells, chromosomes, and formalin-fixed paraffin-embedded tissues</article-title><source>Methods in Molecular Biology</source><volume>1606</volume><fpage>265</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-6990-6_17</pub-id><pub-id pub-id-type="pmid">28502006</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvim</surname><given-names>RGF</given-names></name><name><surname>Lima</surname><given-names>TM</given-names></name><name><surname>Rodrigues</surname><given-names>DAS</given-names></name><name><surname>Marsili</surname><given-names>FF</given-names></name><name><surname>Bozza</surname><given-names>VBT</given-names></name><name><surname>Higa</surname><given-names>LM</given-names></name><name><surname>Monteiro</surname><given-names>FL</given-names></name><name><surname>Leitão</surname><given-names>IC</given-names></name><name><surname>Carvalho</surname><given-names>RS</given-names></name><name><surname>Galliez</surname><given-names>RM</given-names></name><name><surname>Castineiras</surname><given-names>T</given-names></name><name><surname>Nobrega</surname><given-names>A</given-names></name><name><surname>Travassos</surname><given-names>LH</given-names></name><name><surname>Ferreira Jr</surname><given-names>OC</given-names></name><name><surname>Tanuri</surname><given-names>A</given-names></name><name><surname>Vale</surname><given-names>AM</given-names></name><name><surname>Castilho</surname><given-names>LR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An Affordable Anti-SARS-COV-2 Spike Protein Elisa Test for Early Detection of IgG Seroconversion Suited for Large-Scale Surveillance Studies in Low-Income Countries</article-title><source>SSRN Electronic Journal</source><volume>353</volume><elocation-id>131128</elocation-id><pub-id pub-id-type="doi">10.2139/ssrn.3668433</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arunachalam</surname><given-names>PS</given-names></name><name><surname>Wimmers</surname><given-names>F</given-names></name><name><surname>Mok</surname><given-names>CKP</given-names></name><name><surname>Perera</surname><given-names>R</given-names></name><name><surname>Scott</surname><given-names>M</given-names></name><name><surname>Hagan</surname><given-names>T</given-names></name><name><surname>Sigal</surname><given-names>N</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Bristow</surname><given-names>L</given-names></name><name><surname>Tak-Yin Tsang</surname><given-names>O</given-names></name><name><surname>Wagh</surname><given-names>D</given-names></name><name><surname>Coller</surname><given-names>J</given-names></name><name><surname>Pellegrini</surname><given-names>KL</given-names></name><name><surname>Kazmin</surname><given-names>D</given-names></name><name><surname>Alaaeddine</surname><given-names>G</given-names></name><name><surname>Leung</surname><given-names>WS</given-names></name><name><surname>Chan</surname><given-names>JMC</given-names></name><name><surname>Chik</surname><given-names>TSH</given-names></name><name><surname>Choi</surname><given-names>CYC</given-names></name><name><surname>Huerta</surname><given-names>C</given-names></name><name><surname>Paine McCullough</surname><given-names>M</given-names></name><name><surname>Lv</surname><given-names>H</given-names></name><name><surname>Anderson</surname><given-names>E</given-names></name><name><surname>Edupuganti</surname><given-names>S</given-names></name><name><surname>Upadhyay</surname><given-names>AA</given-names></name><name><surname>Bosinger</surname><given-names>SE</given-names></name><name><surname>Maecker</surname><given-names>HT</given-names></name><name><surname>Khatri</surname><given-names>P</given-names></name><name><surname>Rouphael</surname><given-names>N</given-names></name><name><surname>Peiris</surname><given-names>M</given-names></name><name><surname>Pulendran</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans</article-title><source>Science</source><volume>369</volume><fpage>1210</fpage><lpage>1220</lpage><pub-id pub-id-type="doi">10.1126/science.abc6261</pub-id><pub-id pub-id-type="pmid">32788292</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardou</surname><given-names>P</given-names></name><name><surname>Mariette</surname><given-names>J</given-names></name><name><surname>Escudié</surname><given-names>F</given-names></name><name><surname>Djemiel</surname><given-names>C</given-names></name><name><surname>Klopp</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>jvenn: an interactive Venn diagram viewer</article-title><source>BMC Bioinformatics</source><volume>15</volume><elocation-id>293</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-15-293</pub-id><pub-id pub-id-type="pmid">25176396</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bessaud</surname><given-names>M</given-names></name><name><surname>Autret</surname><given-names>A</given-names></name><name><surname>Jegouic</surname><given-names>S</given-names></name><name><surname>Balanant</surname><given-names>J</given-names></name><name><surname>Joffret</surname><given-names>ML</given-names></name><name><surname>Delpeyroux</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Development of a Taqman RT-PCR assay for the detection and quantification of negatively stranded RNA of human enteroviruses: evidence for false-priming and improvement by tagged RT-PCR</article-title><source>Journal of Virological Methods</source><volume>153</volume><fpage>182</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2008.07.010</pub-id><pub-id pub-id-type="pmid">18706930</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>DG</given-names></name><name><surname>Trifilo</surname><given-names>MJ</given-names></name><name><surname>Edelmann</surname><given-names>KH</given-names></name><name><surname>Teyton</surname><given-names>L</given-names></name><name><surname>McGavern</surname><given-names>DB</given-names></name><name><surname>Oldstone</surname><given-names>MBA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Interleukin-10 determines viral clearance or persistence in vivo</article-title><source>Nature Medicine</source><volume>12</volume><fpage>1301</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1038/nm1492</pub-id><pub-id pub-id-type="pmid">17041596</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Candido</surname><given-names>DS</given-names></name><name><surname>Claro</surname><given-names>IM</given-names></name><name><surname>de Jesus</surname><given-names>JG</given-names></name><name><surname>Souza</surname><given-names>WM</given-names></name><name><surname>Moreira</surname><given-names>FRR</given-names></name><name><surname>Dellicour</surname><given-names>S</given-names></name><name><surname>Mellan</surname><given-names>TA</given-names></name><name><surname>du Plessis</surname><given-names>L</given-names></name><name><surname>Pereira</surname><given-names>RHM</given-names></name><name><surname>Sales</surname><given-names>FCS</given-names></name><name><surname>Manuli</surname><given-names>ER</given-names></name><name><surname>Thézé</surname><given-names>J</given-names></name><name><surname>Almeida</surname><given-names>L</given-names></name><name><surname>Menezes</surname><given-names>MT</given-names></name><name><surname>Voloch</surname><given-names>CM</given-names></name><name><surname>Fumagalli</surname><given-names>MJ</given-names></name><name><surname>Coletti</surname><given-names>TM</given-names></name><name><surname>da Silva</surname><given-names>CAM</given-names></name><name><surname>Ramundo</surname><given-names>MS</given-names></name><name><surname>Amorim</surname><given-names>MR</given-names></name><name><surname>Hoeltgebaum</surname><given-names>HH</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Gill</surname><given-names>MS</given-names></name><name><surname>Carvalho</surname><given-names>LM</given-names></name><name><surname>Buss</surname><given-names>LF</given-names></name><name><surname>Prete</surname><given-names>CA</given-names></name><name><surname>Ashworth</surname><given-names>J</given-names></name><name><surname>Nakaya</surname><given-names>HI</given-names></name><name><surname>Peixoto</surname><given-names>PS</given-names></name><name><surname>Brady</surname><given-names>OJ</given-names></name><name><surname>Nicholls</surname><given-names>SM</given-names></name><name><surname>Tanuri</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>ÁD</given-names></name><name><surname>Braga</surname><given-names>CKV</given-names></name><name><surname>Gerber</surname><given-names>AL</given-names></name><name><surname>de C Guimarães</surname><given-names>AP</given-names></name><name><surname>Gaburo</surname><given-names>N</given-names></name><name><surname>Alencar</surname><given-names>CS</given-names></name><name><surname>Ferreira</surname><given-names>ACS</given-names></name><name><surname>Lima</surname><given-names>CX</given-names></name><name><surname>Levi</surname><given-names>JE</given-names></name><name><surname>Granato</surname><given-names>C</given-names></name><name><surname>Ferreira</surname><given-names>GM</given-names></name><name><surname>Francisco</surname><given-names>RS</given-names></name><name><surname>Granja</surname><given-names>F</given-names></name><name><surname>Garcia</surname><given-names>MT</given-names></name><name><surname>Moretti</surname><given-names>ML</given-names></name><name><surname>Perroud</surname><given-names>MW</given-names></name><name><surname>Castiñeiras</surname><given-names>T</given-names></name><name><surname>Lazari</surname><given-names>CS</given-names></name><name><surname>Hill</surname><given-names>SC</given-names></name><name><surname>de Souza Santos</surname><given-names>AA</given-names></name><name><surname>Simeoni</surname><given-names>CL</given-names></name><name><surname>Forato</surname><given-names>J</given-names></name><name><surname>Sposito</surname><given-names>AC</given-names></name><name><surname>Schreiber</surname><given-names>AZ</given-names></name><name><surname>Santos</surname><given-names>MNN</given-names></name><name><surname>de Sá</surname><given-names>CZ</given-names></name><name><surname>Souza</surname><given-names>RP</given-names></name><name><surname>Resende-Moreira</surname><given-names>LC</given-names></name><name><surname>Teixeira</surname><given-names>MM</given-names></name><name><surname>Hubner</surname><given-names>J</given-names></name><name><surname>Leme</surname><given-names>PAF</given-names></name><name><surname>Moreira</surname><given-names>RG</given-names></name><name><surname>Nogueira</surname><given-names>ML</given-names></name><collab>Brazil-UK Centre for Arbovirus Discovery, Diagnosis, Genomics and Epidemiology Genomic Network</collab><name><surname>Ferguson</surname><given-names>NM</given-names></name><name><surname>Costa</surname><given-names>SF</given-names></name><name><surname>Proenca-Modena</surname><given-names>JL</given-names></name><name><surname>Vasconcelos</surname><given-names>ATR</given-names></name><name><surname>Bhatt</surname><given-names>S</given-names></name><name><surname>Lemey</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>CH</given-names></name><name><surname>Rambaut</surname><given-names>A</given-names></name><name><surname>Loman</surname><given-names>NJ</given-names></name><name><surname>Aguiar</surname><given-names>RS</given-names></name><name><surname>Pybus</surname><given-names>OG</given-names></name><name><surname>Sabino</surname><given-names>EC</given-names></name><name><surname>Faria</surname><given-names>NR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evolution and epidemic spread of SARS-CoV-2 in Brazil</article-title><source>Science</source><volume>369</volume><fpage>1255</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1126/science.abd2161</pub-id><pub-id pub-id-type="pmid">32703910</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantuti-Castelvetri</surname><given-names>L</given-names></name><name><surname>Ojha</surname><given-names>R</given-names></name><name><surname>Pedro</surname><given-names>LD</given-names></name><name><surname>Djannatian</surname><given-names>M</given-names></name><name><surname>Franz</surname><given-names>J</given-names></name><name><surname>Kuivanen</surname><given-names>S</given-names></name><name><surname>van der Meer</surname><given-names>F</given-names></name><name><surname>Kallio</surname><given-names>K</given-names></name><name><surname>Kaya</surname><given-names>T</given-names></name><name><surname>Anastasina</surname><given-names>M</given-names></name><name><surname>Smura</surname><given-names>T</given-names></name><name><surname>Levanov</surname><given-names>L</given-names></name><name><surname>Szirovicza</surname><given-names>L</given-names></name><name><surname>Tobi</surname><given-names>A</given-names></name><name><surname>Kallio-Kokko</surname><given-names>H</given-names></name><name><surname>Österlund</surname><given-names>P</given-names></name><name><surname>Joensuu</surname><given-names>M</given-names></name><name><surname>Meunier</surname><given-names>FA</given-names></name><name><surname>Butcher</surname><given-names>SJ</given-names></name><name><surname>Winkler</surname><given-names>MS</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Helenius</surname><given-names>A</given-names></name><name><surname>Gokce</surname><given-names>O</given-names></name><name><surname>Teesalu</surname><given-names>T</given-names></name><name><surname>Hepojoki</surname><given-names>J</given-names></name><name><surname>Vapalahti</surname><given-names>O</given-names></name><name><surname>Stadelmann</surname><given-names>C</given-names></name><name><surname>Balistreri</surname><given-names>G</given-names></name><name><surname>Simons</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity</article-title><source>Science</source><volume>370</volume><fpage>856</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1126/science.abd2985</pub-id><pub-id pub-id-type="pmid">33082293</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cecon</surname><given-names>E</given-names></name><name><surname>Burridge</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Carter</surname><given-names>L</given-names></name><name><surname>Ravichandran</surname><given-names>R</given-names></name><name><surname>Dam</surname><given-names>J</given-names></name><name><surname>Jockers</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET</article-title><source>Cell Chemical Biology</source><volume>29</volume><fpage>74</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2021.06.008</pub-id><pub-id pub-id-type="pmid">34246414</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Codo</surname><given-names>AC</given-names></name><name><surname>Davanzo</surname><given-names>GG</given-names></name><name><surname>Monteiro</surname><given-names>LB</given-names></name><name><surname>de Souza</surname><given-names>GF</given-names></name><name><surname>Muraro</surname><given-names>SP</given-names></name><name><surname>Virgilio-da-Silva</surname><given-names>JV</given-names></name><name><surname>Prodonoff</surname><given-names>JS</given-names></name><name><surname>Carregari</surname><given-names>VC</given-names></name><name><surname>de Biagi Junior</surname><given-names>CAO</given-names></name><name><surname>Crunfli</surname><given-names>F</given-names></name><name><surname>Jimenez Restrepo</surname><given-names>JL</given-names></name><name><surname>Vendramini</surname><given-names>PH</given-names></name><name><surname>Reis-de-Oliveira</surname><given-names>G</given-names></name><name><surname>Bispo Dos Santos</surname><given-names>K</given-names></name><name><surname>Toledo-Teixeira</surname><given-names>DA</given-names></name><name><surname>Parise</surname><given-names>PL</given-names></name><name><surname>Martini</surname><given-names>MC</given-names></name><name><surname>Marques</surname><given-names>RE</given-names></name><name><surname>Carmo</surname><given-names>HR</given-names></name><name><surname>Borin</surname><given-names>A</given-names></name><name><surname>Coimbra</surname><given-names>LD</given-names></name><name><surname>Boldrini</surname><given-names>VO</given-names></name><name><surname>Brunetti</surname><given-names>NS</given-names></name><name><surname>Vieira</surname><given-names>AS</given-names></name><name><surname>Mansour</surname><given-names>E</given-names></name><name><surname>Ulaf</surname><given-names>RG</given-names></name><name><surname>Bernardes</surname><given-names>AF</given-names></name><name><surname>Nunes</surname><given-names>TA</given-names></name><name><surname>Ribeiro</surname><given-names>LC</given-names></name><name><surname>Palma</surname><given-names>AC</given-names></name><name><surname>Agrela</surname><given-names>MV</given-names></name><name><surname>Moretti</surname><given-names>ML</given-names></name><name><surname>Sposito</surname><given-names>AC</given-names></name><name><surname>Pereira</surname><given-names>FB</given-names></name><name><surname>Velloso</surname><given-names>LA</given-names></name><name><surname>Vinolo</surname><given-names>MAR</given-names></name><name><surname>Damasio</surname><given-names>A</given-names></name><name><surname>Proença-Módena</surname><given-names>JL</given-names></name><name><surname>Carvalho</surname><given-names>RF</given-names></name><name><surname>Mori</surname><given-names>MA</given-names></name><name><surname>Martins-de-Souza</surname><given-names>D</given-names></name><name><surname>Nakaya</surname><given-names>HI</given-names></name><name><surname>Farias</surname><given-names>AS</given-names></name><name><surname>Moraes-Vieira</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis</article-title><source>Cell Metabolism</source><volume>32</volume><fpage>498</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.07.015</pub-id><pub-id pub-id-type="pmid">32877692</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crunfli</surname><given-names>F</given-names></name><name><surname>Carregari</surname><given-names>VC</given-names></name><name><surname>Veras</surname><given-names>FP</given-names></name><name><surname>Silva</surname><given-names>LS</given-names></name><name><surname>Nogueira</surname><given-names>MH</given-names></name><name><surname>Antunes</surname><given-names>A</given-names></name><name><surname>Vendramini</surname><given-names>PH</given-names></name><name><surname>Valença</surname><given-names>AGF</given-names></name><name><surname>Brandão-Teles</surname><given-names>C</given-names></name><name><surname>Zuccoli</surname><given-names>GS</given-names></name><name><surname>Reis-de-Oliveira</surname><given-names>G</given-names></name><name><surname>Silva-Costa</surname><given-names>LC</given-names></name><name><surname>Saia-Cereda</surname><given-names>VM</given-names></name><name><surname>Smith</surname><given-names>BJ</given-names></name><name><surname>Codo</surname><given-names>AC</given-names></name><name><surname>de Souza</surname><given-names>GF</given-names></name><name><surname>Muraro</surname><given-names>SP</given-names></name><name><surname>Parise</surname><given-names>PL</given-names></name><name><surname>Toledo-Teixeira</surname><given-names>DA</given-names></name><name><surname>Santos de Castro</surname><given-names>ÍM</given-names></name><name><surname>Melo</surname><given-names>BM</given-names></name><name><surname>Almeida</surname><given-names>GM</given-names></name><name><surname>Firmino</surname><given-names>EMS</given-names></name><name><surname>Paiva</surname><given-names>IM</given-names></name><name><surname>Silva</surname><given-names>BMS</given-names></name><name><surname>Guimarães</surname><given-names>RM</given-names></name><name><surname>Mendes</surname><given-names>ND</given-names></name><name><surname>Ludwig</surname><given-names>RL</given-names></name><name><surname>Ruiz</surname><given-names>GP</given-names></name><name><surname>Knittel</surname><given-names>TL</given-names></name><name><surname>Davanzo</surname><given-names>GG</given-names></name><name><surname>Gerhardt</surname><given-names>JA</given-names></name><name><surname>Rodrigues</surname><given-names>PB</given-names></name><name><surname>Forato</surname><given-names>J</given-names></name><name><surname>Amorim</surname><given-names>MR</given-names></name><name><surname>Brunetti</surname><given-names>NS</given-names></name><name><surname>Martini</surname><given-names>MC</given-names></name><name><surname>Benatti</surname><given-names>MN</given-names></name><name><surname>Batah</surname><given-names>SS</given-names></name><name><surname>Siyuan</surname><given-names>L</given-names></name><name><surname>João</surname><given-names>RB</given-names></name><name><surname>Aventurato</surname><given-names>ÍK</given-names></name><name><surname>Rabelo de Brito</surname><given-names>M</given-names></name><name><surname>Mendes</surname><given-names>MJ</given-names></name><name><surname>da Costa</surname><given-names>BA</given-names></name><name><surname>Alvim</surname><given-names>MKM</given-names></name><name><surname>da Silva Júnior</surname><given-names>JR</given-names></name><name><surname>Damião</surname><given-names>LL</given-names></name><name><surname>de Sousa</surname><given-names>IMP</given-names></name><name><surname>da Rocha</surname><given-names>ED</given-names></name><name><surname>Gonçalves</surname><given-names>SM</given-names></name><name><surname>Lopes da Silva</surname><given-names>LH</given-names></name><name><surname>Bettini</surname><given-names>V</given-names></name><name><surname>Campos</surname><given-names>BM</given-names></name><name><surname>Ludwig</surname><given-names>G</given-names></name><name><surname>Tavares</surname><given-names>LA</given-names></name><name><surname>Pontelli</surname><given-names>MC</given-names></name><name><surname>Viana</surname><given-names>RMM</given-names></name><name><surname>Martins</surname><given-names>RB</given-names></name><name><surname>Vieira</surname><given-names>AS</given-names></name><name><surname>Alves-Filho</surname><given-names>JC</given-names></name><name><surname>Arruda</surname><given-names>E</given-names></name><name><surname>Podolsky-Gondim</surname><given-names>GG</given-names></name><name><surname>Santos</surname><given-names>MV</given-names></name><name><surname>Neder</surname><given-names>L</given-names></name><name><surname>Damasio</surname><given-names>A</given-names></name><name><surname>Rehen</surname><given-names>S</given-names></name><name><surname>Vinolo</surname><given-names>MAR</given-names></name><name><surname>Munhoz</surname><given-names>CD</given-names></name><name><surname>Louzada-Junior</surname><given-names>P</given-names></name><name><surname>Oliveira</surname><given-names>RD</given-names></name><name><surname>Cunha</surname><given-names>FQ</given-names></name><name><surname>Nakaya</surname><given-names>HI</given-names></name><name><surname>Mauad</surname><given-names>T</given-names></name><name><surname>Duarte-Neto</surname><given-names>AN</given-names></name><name><surname>Ferraz da Silva</surname><given-names>LF</given-names></name><name><surname>Dolhnikoff</surname><given-names>M</given-names></name><name><surname>Saldiva</surname><given-names>PHN</given-names></name><name><surname>Farias</surname><given-names>AS</given-names></name><name><surname>Cendes</surname><given-names>F</given-names></name><name><surname>Moraes-Vieira</surname><given-names>PMM</given-names></name><name><surname>Fabro</surname><given-names>AT</given-names></name><name><surname>Sebollela</surname><given-names>A</given-names></name><name><surname>Proença-Modena</surname><given-names>JL</given-names></name><name><surname>Yasuda</surname><given-names>CL</given-names></name><name><surname>Mori</surname><given-names>MA</given-names></name><name><surname>Cunha</surname><given-names>TM</given-names></name><name><surname>Martins-de-Souza</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Morphological, cellular, and molecular basis of brain infection in COVID-19 patients</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2200960119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2200960119</pub-id><pub-id pub-id-type="pmid">35951647</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darden</surname><given-names>T</given-names></name><name><surname>York</surname><given-names>D</given-names></name><name><surname>Pedersen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems</article-title><source>The Journal of Chemical Physics</source><volume>98</volume><fpage>10089</fpage><lpage>10092</lpage><pub-id pub-id-type="doi">10.1063/1.464397</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>PJ</given-names></name><name><surname>Bevan</surname><given-names>IS</given-names></name><name><surname>Gurney</surname><given-names>SJ</given-names></name><name><surname>Young</surname><given-names>LS</given-names></name><name><surname>Walker</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Synthesis in vitro and application of biotinylated DNA probes for human papilloma virus type 16 by utilizing the polymerase chain reaction</article-title><source>The Biochemical Journal</source><volume>267</volume><fpage>119</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1042/bj2670119</pub-id><pub-id pub-id-type="pmid">2158305</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Biasi</surname><given-names>S</given-names></name><name><surname>Meschiari</surname><given-names>M</given-names></name><name><surname>Gibellini</surname><given-names>L</given-names></name><name><surname>Bellinazzi</surname><given-names>C</given-names></name><name><surname>Borella</surname><given-names>R</given-names></name><name><surname>Fidanza</surname><given-names>L</given-names></name><name><surname>Gozzi</surname><given-names>L</given-names></name><name><surname>Iannone</surname><given-names>A</given-names></name><name><surname>Lo Tartaro</surname><given-names>D</given-names></name><name><surname>Mattioli</surname><given-names>M</given-names></name><name><surname>Paolini</surname><given-names>A</given-names></name><name><surname>Menozzi</surname><given-names>M</given-names></name><name><surname>Milić</surname><given-names>J</given-names></name><name><surname>Franceschi</surname><given-names>G</given-names></name><name><surname>Fantini</surname><given-names>R</given-names></name><name><surname>Tonelli</surname><given-names>R</given-names></name><name><surname>Sita</surname><given-names>M</given-names></name><name><surname>Sarti</surname><given-names>M</given-names></name><name><surname>Trenti</surname><given-names>T</given-names></name><name><surname>Brugioni</surname><given-names>L</given-names></name><name><surname>Cicchetti</surname><given-names>L</given-names></name><name><surname>Facchinetti</surname><given-names>F</given-names></name><name><surname>Pietrangelo</surname><given-names>A</given-names></name><name><surname>Clini</surname><given-names>E</given-names></name><name><surname>Girardis</surname><given-names>M</given-names></name><name><surname>Guaraldi</surname><given-names>G</given-names></name><name><surname>Mussini</surname><given-names>C</given-names></name><name><surname>Cossarizza</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3434</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17292-4</pub-id><pub-id pub-id-type="pmid">32632085</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>LG</given-names></name><name><surname>de Souza Angelo</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>P</given-names></name><name><surname>Carregari</surname><given-names>VC</given-names></name><name><surname>Crunfli</surname><given-names>F</given-names></name><name><surname>Reis-de-Oliveira</surname><given-names>G</given-names></name><name><surname>Costa</surname><given-names>L</given-names></name><name><surname>Vendramini</surname><given-names>PH</given-names></name><name><surname>Duque</surname><given-names>ÉA</given-names></name><name><surname>Dos Santos</surname><given-names>NB</given-names></name><name><surname>Firmino</surname><given-names>EM</given-names></name><name><surname>Paiva</surname><given-names>IM</given-names></name><name><surname>Almeida</surname><given-names>GM</given-names></name><name><surname>Sebollela</surname><given-names>A</given-names></name><name><surname>Polonio</surname><given-names>CM</given-names></name><name><surname>Zanluqui</surname><given-names>NG</given-names></name><name><surname>de Oliveira</surname><given-names>MG</given-names></name><name><surname>da Silva</surname><given-names>P</given-names></name><name><surname>Davanzo</surname><given-names>GG</given-names></name><name><surname>Ayupe</surname><given-names>MC</given-names></name><name><surname>Salgado</surname><given-names>CL</given-names></name><name><surname>de Souza Filho</surname><given-names>AF</given-names></name><name><surname>de Araújo</surname><given-names>MV</given-names></name><name><surname>Silva-Pereira</surname><given-names>TT</given-names></name><name><surname>de Almeida Campos</surname><given-names>AC</given-names></name><name><surname>Góes</surname><given-names>LGB</given-names></name><name><surname>Dos Passos Cunha</surname><given-names>M</given-names></name><name><surname>Caldini</surname><given-names>EG</given-names></name><name><surname>D’Império Lima</surname><given-names>MR</given-names></name><name><surname>Fonseca</surname><given-names>DM</given-names></name><name><surname>de Sá Guimarães</surname><given-names>AM</given-names></name><name><surname>Minoprio</surname><given-names>PC</given-names></name><name><surname>Munhoz</surname><given-names>CD</given-names></name><name><surname>Mori</surname><given-names>CMC</given-names></name><name><surname>Moraes-Vieira</surname><given-names>PM</given-names></name><name><surname>Cunha</surname><given-names>TM</given-names></name><name><surname>Martins-de-Souza</surname><given-names>D</given-names></name><name><surname>Peron</surname><given-names>JPS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2 infection impacts carbon metabolism and depends on glutamine for replication in Syrian hamster astrocytes</article-title><source>Journal of Neurochemistry</source><volume>163</volume><fpage>113</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1111/jnc.15679</pub-id><pub-id pub-id-type="pmid">35880385</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Distler</surname><given-names>U</given-names></name><name><surname>Kuharev</surname><given-names>J</given-names></name><name><surname>Navarro</surname><given-names>P</given-names></name><name><surname>Tenzer</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Label-free quantification in ion mobility-enhanced data-independent acquisition proteomics</article-title><source>Nature Protocols</source><volume>11</volume><fpage>795</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1038/nprot.2016.042</pub-id><pub-id pub-id-type="pmid">27010757</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>AJR</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Cd4-RBD-interaction-models</data-title><version designator="swh:1:rev:bdd026cc1403b1a17ebb86a06ac50b65454740f5">swh:1:rev:bdd026cc1403b1a17ebb86a06ac50b65454740f5</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:a0cca14cdc546ab48de8602c39575edae76baace;origin=https://github.com/ajrferrari/CD4-RBD-interaction-models;visit=swh:1:snp:f7ca474979de5c7c4a638d8b38f383e728739a2e;anchor=swh:1:rev:bdd026cc1403b1a17ebb86a06ac50b65454740f5">https://archive.softwareheritage.org/swh:1:dir:a0cca14cdc546ab48de8602c39575edae76baace;origin=https://github.com/ajrferrari/CD4-RBD-interaction-models;visit=swh:1:snp:f7ca474979de5c7c4a638d8b38f383e728739a2e;anchor=swh:1:rev:bdd026cc1403b1a17ebb86a06ac50b65454740f5</ext-link></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fields</surname><given-names>GB</given-names></name><name><surname>Noble</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids</article-title><source>International Journal of Peptide and Protein Research</source><volume>35</volume><fpage>161</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1111/j.1399-3011.1990.tb00939.x</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folks</surname><given-names>T</given-names></name><name><surname>Benn</surname><given-names>S</given-names></name><name><surname>Rabson</surname><given-names>A</given-names></name><name><surname>Theodore</surname><given-names>T</given-names></name><name><surname>Hoggan</surname><given-names>MD</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Lightfoote</surname><given-names>M</given-names></name><name><surname>Sell</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus</article-title><source>PNAS</source><volume>82</volume><fpage>4539</fpage><lpage>4543</lpage><pub-id pub-id-type="doi">10.1073/pnas.82.13.4539</pub-id><pub-id pub-id-type="pmid">2989831</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folks</surname><given-names>T</given-names></name><name><surname>Powell</surname><given-names>DM</given-names></name><name><surname>Lightfoote</surname><given-names>MM</given-names></name><name><surname>Benn</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>MA</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency</article-title><source>Science</source><volume>231</volume><fpage>600</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1126/science.3003906</pub-id><pub-id pub-id-type="pmid">3003906</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasteiger</surname><given-names>G</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Interactions between innate and adaptive lymphocytes</article-title><source>Nature Reviews. Immunology</source><volume>14</volume><fpage>631</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1038/nri3726</pub-id><pub-id pub-id-type="pmid">25132095</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gee</surname><given-names>K</given-names></name><name><surname>Angel</surname><given-names>JB</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Gajanayaka</surname><given-names>N</given-names></name><name><surname>Parato</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Intracellular HIV-Tat expression induces IL-10 synthesis by the CREB-1 transcription factor through Ser133 phosphorylation and its regulation by the ERK1/2 MAPK in human monocytic cells</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>31647</fpage><lpage>31658</lpage><pub-id pub-id-type="doi">10.1074/jbc.M512109200</pub-id><pub-id pub-id-type="pmid">16920714</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadjadj</surname><given-names>J</given-names></name><name><surname>Yatim</surname><given-names>N</given-names></name><name><surname>Barnabei</surname><given-names>L</given-names></name><name><surname>Corneau</surname><given-names>A</given-names></name><name><surname>Boussier</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>N</given-names></name><name><surname>Péré</surname><given-names>H</given-names></name><name><surname>Charbit</surname><given-names>B</given-names></name><name><surname>Bondet</surname><given-names>V</given-names></name><name><surname>Chenevier-Gobeaux</surname><given-names>C</given-names></name><name><surname>Breillat</surname><given-names>P</given-names></name><name><surname>Carlier</surname><given-names>N</given-names></name><name><surname>Gauzit</surname><given-names>R</given-names></name><name><surname>Morbieu</surname><given-names>C</given-names></name><name><surname>Pène</surname><given-names>F</given-names></name><name><surname>Marin</surname><given-names>N</given-names></name><name><surname>Roche</surname><given-names>N</given-names></name><name><surname>Szwebel</surname><given-names>TA</given-names></name><name><surname>Merkling</surname><given-names>SH</given-names></name><name><surname>Treluyer</surname><given-names>JM</given-names></name><name><surname>Veyer</surname><given-names>D</given-names></name><name><surname>Mouthon</surname><given-names>L</given-names></name><name><surname>Blanc</surname><given-names>C</given-names></name><name><surname>Tharaux</surname><given-names>PL</given-names></name><name><surname>Rozenberg</surname><given-names>F</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Duffy</surname><given-names>D</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name><name><surname>Kernéis</surname><given-names>S</given-names></name><name><surname>Terrier</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients</article-title><source>Science</source><volume>369</volume><fpage>718</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1126/science.abc6027</pub-id><pub-id pub-id-type="pmid">32661059</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors</article-title><source>Emerging Microbes &amp; Infections</source><volume>9</volume><fpage>1123</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1770129</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Krüger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><name><surname>Schiergens</surname><given-names>TS</given-names></name><name><surname>Herrler</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>NH</given-names></name><name><surname>Nitsche</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Pöhlmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title><source>Cell</source><volume>181</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>W</given-names></name><name><surname>Dalke</surname><given-names>A</given-names></name><name><surname>Schulten</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>VMD: visual molecular dynamics</article-title><source>Journal of Molecular Graphics</source><volume>14</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/0263-7855(96)00018-5</pub-id><pub-id pub-id-type="pmid">8744570</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>WL</given-names></name><name><surname>Chandrasekhar</surname><given-names>J</given-names></name><name><surname>Madura</surname><given-names>JD</given-names></name><name><surname>Impey</surname><given-names>RW</given-names></name><name><surname>Klein</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Comparison of simple potential functions for simulating liquid water</article-title><source>The Journal of Chemical Physics</source><volume>79</volume><fpage>926</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1063/1.445869</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirschner</surname><given-names>KN</given-names></name><name><surname>Yongye</surname><given-names>AB</given-names></name><name><surname>Tschampel</surname><given-names>SM</given-names></name><name><surname>González-Outeiriño</surname><given-names>J</given-names></name><name><surname>Daniels</surname><given-names>CR</given-names></name><name><surname>Foley</surname><given-names>BL</given-names></name><name><surname>Woods</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>GLYCAM06: A generalizable biomolecular force field. Carbohydrates</article-title><source>Journal of Computational Chemistry</source><volume>29</volume><fpage>622</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1002/jcc.20820</pub-id><pub-id pub-id-type="pmid">17849372</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuleshov</surname><given-names>MV</given-names></name><name><surname>Jones</surname><given-names>MR</given-names></name><name><surname>Rouillard</surname><given-names>AD</given-names></name><name><surname>Fernandez</surname><given-names>NF</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Koplev</surname><given-names>S</given-names></name><name><surname>Jenkins</surname><given-names>SL</given-names></name><name><surname>Jagodnik</surname><given-names>KM</given-names></name><name><surname>Lachmann</surname><given-names>A</given-names></name><name><surname>McDermott</surname><given-names>MG</given-names></name><name><surname>Monteiro</surname><given-names>CD</given-names></name><name><surname>Gundersen</surname><given-names>GW</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Enrichr: a comprehensive gene set enrichment analysis web server 2016 update</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>W90</fpage><lpage>W97</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw377</pub-id><pub-id pub-id-type="pmid">27141961</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laing</surname><given-names>AG</given-names></name><name><surname>Lorenc</surname><given-names>A</given-names></name><name><surname>del Molino del Barrio</surname><given-names>I</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Fish</surname><given-names>M</given-names></name><name><surname>Monin</surname><given-names>L</given-names></name><name><surname>Muñoz-Ruiz</surname><given-names>M</given-names></name><name><surname>McKenzie</surname><given-names>DR</given-names></name><name><surname>Hayday</surname><given-names>TS</given-names></name><name><surname>Francos-Quijorna</surname><given-names>I</given-names></name><name><surname>Kamdar</surname><given-names>S</given-names></name><name><surname>Joseph</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>D</given-names></name><name><surname>Davis</surname><given-names>R</given-names></name><name><surname>Jennings</surname><given-names>A</given-names></name><name><surname>Zlatareva</surname><given-names>I</given-names></name><name><surname>Vantourout</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Sofra</surname><given-names>V</given-names></name><name><surname>Cano</surname><given-names>F</given-names></name><name><surname>Greco</surname><given-names>M</given-names></name><name><surname>Theodoridis</surname><given-names>E</given-names></name><name><surname>Freedman</surname><given-names>JD</given-names></name><name><surname>Gee</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>JNE</given-names></name><name><surname>Ryan</surname><given-names>S</given-names></name><name><surname>Bugallo-Blanco</surname><given-names>E</given-names></name><name><surname>Peterson</surname><given-names>P</given-names></name><name><surname>Kisand</surname><given-names>K</given-names></name><name><surname>Haljasmägi</surname><given-names>L</given-names></name><name><surname>Chadli</surname><given-names>L</given-names></name><name><surname>Moingeon</surname><given-names>P</given-names></name><name><surname>Martinez</surname><given-names>L</given-names></name><name><surname>Merrick</surname><given-names>B</given-names></name><name><surname>Bisnauthsing</surname><given-names>K</given-names></name><name><surname>Brooks</surname><given-names>K</given-names></name><name><surname>Ibrahim</surname><given-names>MAA</given-names></name><name><surname>Mason</surname><given-names>J</given-names></name><name><surname>Lopez Gomez</surname><given-names>F</given-names></name><name><surname>Babalola</surname><given-names>K</given-names></name><name><surname>Abdul-Jawad</surname><given-names>S</given-names></name><name><surname>Cason</surname><given-names>J</given-names></name><name><surname>Mant</surname><given-names>C</given-names></name><name><surname>Seow</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>C</given-names></name><name><surname>Doores</surname><given-names>KJ</given-names></name><name><surname>Di Rosa</surname><given-names>F</given-names></name><name><surname>Edgeworth</surname><given-names>J</given-names></name><name><surname>Shankar-Hari</surname><given-names>M</given-names></name><name><surname>Hayday</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A dynamic COVID-19 immune signature includes associations with poor prognosis</article-title><source>Nature Medicine</source><volume>26</volume><fpage>1623</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-1038-6</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>MM</given-names></name><name><surname>Beumer</surname><given-names>J</given-names></name><name><surname>van der Vaart</surname><given-names>J</given-names></name><name><surname>Knoops</surname><given-names>K</given-names></name><name><surname>Puschhof</surname><given-names>J</given-names></name><name><surname>Breugem</surname><given-names>TI</given-names></name><name><surname>Ravelli</surname><given-names>RBG</given-names></name><name><surname>Paul van Schayck</surname><given-names>J</given-names></name><name><surname>Mykytyn</surname><given-names>AZ</given-names></name><name><surname>Duimel</surname><given-names>HQ</given-names></name><name><surname>van Donselaar</surname><given-names>E</given-names></name><name><surname>Riesebosch</surname><given-names>S</given-names></name><name><surname>Kuijpers</surname><given-names>HJH</given-names></name><name><surname>Schipper</surname><given-names>D</given-names></name><name><surname>van de Wetering</surname><given-names>WJ</given-names></name><name><surname>de Graaf</surname><given-names>M</given-names></name><name><surname>Koopmans</surname><given-names>M</given-names></name><name><surname>Cuppen</surname><given-names>E</given-names></name><name><surname>Peters</surname><given-names>PJ</given-names></name><name><surname>Haagmans</surname><given-names>BL</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 productively infects human gut enterocytes</article-title><source>Science</source><volume>369</volume><fpage>50</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1126/science.abc1669</pub-id><pub-id pub-id-type="pmid">32358202</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasso</surname><given-names>G</given-names></name><name><surname>Mayer</surname><given-names>SV</given-names></name><name><surname>Winkelmann</surname><given-names>ER</given-names></name><name><surname>Chu</surname><given-names>T</given-names></name><name><surname>Elliot</surname><given-names>O</given-names></name><name><surname>Patino-Galindo</surname><given-names>JA</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Rabadan</surname><given-names>R</given-names></name><name><surname>Honig</surname><given-names>B</given-names></name><name><surname>Shapira</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A structure-informed atlas of human-virus interactions</article-title><source>Cell</source><volume>178</volume><fpage>1526</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.08.005</pub-id><pub-id pub-id-type="pmid">31474372</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leman</surname><given-names>JK</given-names></name><name><surname>Weitzner</surname><given-names>BD</given-names></name><name><surname>Lewis</surname><given-names>SM</given-names></name><name><surname>Adolf-Bryfogle</surname><given-names>J</given-names></name><name><surname>Alam</surname><given-names>N</given-names></name><name><surname>Alford</surname><given-names>RF</given-names></name><name><surname>Aprahamian</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>Barlow</surname><given-names>KA</given-names></name><name><surname>Barth</surname><given-names>P</given-names></name><name><surname>Basanta</surname><given-names>B</given-names></name><name><surname>Bender</surname><given-names>BJ</given-names></name><name><surname>Blacklock</surname><given-names>K</given-names></name><name><surname>Bonet</surname><given-names>J</given-names></name><name><surname>Boyken</surname><given-names>SE</given-names></name><name><surname>Bradley</surname><given-names>P</given-names></name><name><surname>Bystroff</surname><given-names>C</given-names></name><name><surname>Conway</surname><given-names>P</given-names></name><name><surname>Cooper</surname><given-names>S</given-names></name><name><surname>Correia</surname><given-names>BE</given-names></name><name><surname>Coventry</surname><given-names>B</given-names></name><name><surname>Das</surname><given-names>R</given-names></name><name><surname>De Jong</surname><given-names>RM</given-names></name><name><surname>DiMaio</surname><given-names>F</given-names></name><name><surname>Dsilva</surname><given-names>L</given-names></name><name><surname>Dunbrack</surname><given-names>R</given-names></name><name><surname>Ford</surname><given-names>AS</given-names></name><name><surname>Frenz</surname><given-names>B</given-names></name><name><surname>Fu</surname><given-names>DY</given-names></name><name><surname>Geniesse</surname><given-names>C</given-names></name><name><surname>Goldschmidt</surname><given-names>L</given-names></name><name><surname>Gowthaman</surname><given-names>R</given-names></name><name><surname>Gray</surname><given-names>JJ</given-names></name><name><surname>Gront</surname><given-names>D</given-names></name><name><surname>Guffy</surname><given-names>S</given-names></name><name><surname>Horowitz</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>P-S</given-names></name><name><surname>Huber</surname><given-names>T</given-names></name><name><surname>Jacobs</surname><given-names>TM</given-names></name><name><surname>Jeliazkov</surname><given-names>JR</given-names></name><name><surname>Johnson</surname><given-names>DK</given-names></name><name><surname>Kappel</surname><given-names>K</given-names></name><name><surname>Karanicolas</surname><given-names>J</given-names></name><name><surname>Khakzad</surname><given-names>H</given-names></name><name><surname>Khar</surname><given-names>KR</given-names></name><name><surname>Khare</surname><given-names>SD</given-names></name><name><surname>Khatib</surname><given-names>F</given-names></name><name><surname>Khramushin</surname><given-names>A</given-names></name><name><surname>King</surname><given-names>IC</given-names></name><name><surname>Kleffner</surname><given-names>R</given-names></name><name><surname>Koepnick</surname><given-names>B</given-names></name><name><surname>Kortemme</surname><given-names>T</given-names></name><name><surname>Kuenze</surname><given-names>G</given-names></name><name><surname>Kuhlman</surname><given-names>B</given-names></name><name><surname>Kuroda</surname><given-names>D</given-names></name><name><surname>Labonte</surname><given-names>JW</given-names></name><name><surname>Lai</surname><given-names>JK</given-names></name><name><surname>Lapidoth</surname><given-names>G</given-names></name><name><surname>Leaver-Fay</surname><given-names>A</given-names></name><name><surname>Lindert</surname><given-names>S</given-names></name><name><surname>Linsky</surname><given-names>T</given-names></name><name><surname>London</surname><given-names>N</given-names></name><name><surname>Lubin</surname><given-names>JH</given-names></name><name><surname>Lyskov</surname><given-names>S</given-names></name><name><surname>Maguire</surname><given-names>J</given-names></name><name><surname>Malmström</surname><given-names>L</given-names></name><name><surname>Marcos</surname><given-names>E</given-names></name><name><surname>Marcu</surname><given-names>O</given-names></name><name><surname>Marze</surname><given-names>NA</given-names></name><name><surname>Meiler</surname><given-names>J</given-names></name><name><surname>Moretti</surname><given-names>R</given-names></name><name><surname>Mulligan</surname><given-names>VK</given-names></name><name><surname>Nerli</surname><given-names>S</given-names></name><name><surname>Norn</surname><given-names>C</given-names></name><name><surname>Ó’Conchúir</surname><given-names>S</given-names></name><name><surname>Ollikainen</surname><given-names>N</given-names></name><name><surname>Ovchinnikov</surname><given-names>S</given-names></name><name><surname>Pacella</surname><given-names>MS</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Pavlovicz</surname><given-names>RE</given-names></name><name><surname>Pethe</surname><given-names>M</given-names></name><name><surname>Pierce</surname><given-names>BG</given-names></name><name><surname>Pilla</surname><given-names>KB</given-names></name><name><surname>Raveh</surname><given-names>B</given-names></name><name><surname>Renfrew</surname><given-names>PD</given-names></name><name><surname>Burman</surname><given-names>SSR</given-names></name><name><surname>Rubenstein</surname><given-names>A</given-names></name><name><surname>Sauer</surname><given-names>MF</given-names></name><name><surname>Scheck</surname><given-names>A</given-names></name><name><surname>Schief</surname><given-names>W</given-names></name><name><surname>Schueler-Furman</surname><given-names>O</given-names></name><name><surname>Sedan</surname><given-names>Y</given-names></name><name><surname>Sevy</surname><given-names>AM</given-names></name><name><surname>Sgourakis</surname><given-names>NG</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Siegel</surname><given-names>JB</given-names></name><name><surname>Silva</surname><given-names>D-A</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Stein</surname><given-names>A</given-names></name><name><surname>Szegedy</surname><given-names>M</given-names></name><name><surname>Teets</surname><given-names>FD</given-names></name><name><surname>Thyme</surname><given-names>SB</given-names></name><name><surname>Wang</surname><given-names>RY-R</given-names></name><name><surname>Watkins</surname><given-names>A</given-names></name><name><surname>Zimmerman</surname><given-names>L</given-names></name><name><surname>Bonneau</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Macromolecular modeling and design in Rosetta: recent methods and frameworks</article-title><source>Nature Methods</source><volume>17</volume><fpage>665</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/s41592-020-0848-2</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Pei</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Shaman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)</article-title><source>Science</source><volume>368</volume><fpage>489</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1126/science.abb3221</pub-id><pub-id pub-id-type="pmid">32179701</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>PH</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Ou</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed PI3K/AKT/mTOR signaling</article-title><source>Biochimica et Biophysica Acta. Molecular Basis of Disease</source><volume>1867</volume><elocation-id>166260</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbadis.2021.166260</pub-id><pub-id pub-id-type="pmid">34461258</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19</article-title><source>Nature Medicine</source><volume>26</volume><fpage>842</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0901-9</pub-id><pub-id pub-id-type="pmid">32398875</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>QX</given-names></name><name><surname>Tang</surname><given-names>XJ</given-names></name><name><surname>Shi</surname><given-names>QL</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Deng</surname><given-names>HJ</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>JL</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>FJ</given-names></name><name><surname>Su</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>XM</given-names></name><name><surname>Li</surname><given-names>JJ</given-names></name><name><surname>Qiu</surname><given-names>JF</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections</article-title><source>Nature Medicine</source><volume>26</volume><fpage>1200</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0965-6</pub-id><pub-id pub-id-type="pmid">32555424</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>MR</given-names></name><name><surname>Pantano</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Split the charge difference in two! a rule of thumb for adding proper amounts of ions in md simulations</article-title><source>Journal of Chemical Theory and Computation</source><volume>16</volume><fpage>1367</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.9b00953</pub-id><pub-id pub-id-type="pmid">31999456</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>JA</given-names></name><name><surname>Martinez</surname><given-names>C</given-names></name><name><surname>Kasavajhala</surname><given-names>K</given-names></name><name><surname>Wickstrom</surname><given-names>L</given-names></name><name><surname>Hauser</surname><given-names>KE</given-names></name><name><surname>Simmerling</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB</article-title><source>Journal of Chemical Theory and Computation</source><volume>11</volume><fpage>3696</fpage><lpage>3713</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.5b00255</pub-id><pub-id pub-id-type="pmid">26574453</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez</surname><given-names>L</given-names></name><name><surname>Andreani</surname><given-names>R</given-names></name><name><surname>Martínez</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Convergent algorithms for protein structural alignment</article-title><source>BMC Bioinformatics</source><volume>8</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1186/1471-2105-8-306</pub-id><pub-id pub-id-type="pmid">17714583</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marze</surname><given-names>NA</given-names></name><name><surname>Roy Burman</surname><given-names>SS</given-names></name><name><surname>Sheffler</surname><given-names>W</given-names></name><name><surname>Gray</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Efficient flexible backbone protein-protein docking for challenging targets</article-title><source>Bioinformatics</source><volume>34</volume><fpage>3461</fpage><lpage>3469</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty355</pub-id><pub-id pub-id-type="pmid">29718115</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>D</given-names></name><name><surname>Giles</surname><given-names>JR</given-names></name><name><surname>Baxter</surname><given-names>AE</given-names></name><name><surname>Oldridge</surname><given-names>DA</given-names></name><name><surname>Greenplate</surname><given-names>AR</given-names></name><name><surname>Wu</surname><given-names>JE</given-names></name><name><surname>Alanio</surname><given-names>C</given-names></name><name><surname>Kuri-Cervantes</surname><given-names>L</given-names></name><name><surname>Pampena</surname><given-names>MB</given-names></name><name><surname>D’Andrea</surname><given-names>K</given-names></name><name><surname>Manne</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>YJ</given-names></name><name><surname>Reilly</surname><given-names>JP</given-names></name><name><surname>Weisman</surname><given-names>AR</given-names></name><name><surname>Ittner</surname><given-names>CAG</given-names></name><name><surname>Kuthuru</surname><given-names>O</given-names></name><name><surname>Dougherty</surname><given-names>J</given-names></name><name><surname>Nzingha</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Pattekar</surname><given-names>A</given-names></name><name><surname>Goodwin</surname><given-names>EC</given-names></name><name><surname>Anderson</surname><given-names>EM</given-names></name><name><surname>Weirick</surname><given-names>ME</given-names></name><name><surname>Gouma</surname><given-names>S</given-names></name><name><surname>Arevalo</surname><given-names>CP</given-names></name><name><surname>Bolton</surname><given-names>MJ</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Lacey</surname><given-names>SF</given-names></name><name><surname>Ramage</surname><given-names>H</given-names></name><name><surname>Cherry</surname><given-names>S</given-names></name><name><surname>Hensley</surname><given-names>SE</given-names></name><name><surname>Apostolidis</surname><given-names>SA</given-names></name><name><surname>Huang</surname><given-names>AC</given-names></name><name><surname>Vella</surname><given-names>LA</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Meyer</surname><given-names>NJ</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><collab>UPenn COVID Processing Unit</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications</article-title><source>Science</source><volume>369</volume><elocation-id>eabc8511</elocation-id><pub-id pub-id-type="doi">10.1126/science.abc8511</pub-id><pub-id pub-id-type="pmid">32669297</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>JB</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cytokine release syndrome in severe COVID-19</article-title><source>Science</source><volume>368</volume><fpage>473</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1126/science.abb8925</pub-id><pub-id pub-id-type="pmid">32303591</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Shea</surname><given-names>JJ</given-names></name><name><surname>Paul</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells</article-title><source>Science</source><volume>327</volume><fpage>1098</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1126/science.1178334</pub-id><pub-id pub-id-type="pmid">20185720</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascoal</surname><given-names>LB</given-names></name><name><surname>Rodrigues</surname><given-names>PB</given-names></name><name><surname>Genaro</surname><given-names>LM</given-names></name><name><surname>Gomes</surname><given-names>AB</given-names></name><name><surname>Toledo-Teixeira</surname><given-names>DA</given-names></name><name><surname>Parise</surname><given-names>PL</given-names></name><name><surname>Bispo-Dos-Santos</surname><given-names>K</given-names></name><name><surname>Simeoni</surname><given-names>CL</given-names></name><name><surname>Guimarães</surname><given-names>PV</given-names></name><name><surname>Buscaratti</surname><given-names>LI</given-names></name><name><surname>Elston</surname><given-names>JGDA</given-names></name><name><surname>Marques-Souza</surname><given-names>H</given-names></name><name><surname>Martins-de-Souza</surname><given-names>D</given-names></name><name><surname>Ayrizono</surname><given-names>MDLS</given-names></name><name><surname>Velloso</surname><given-names>LA</given-names></name><name><surname>Proenca-Modena</surname><given-names>JL</given-names></name><name><surname>Moraes-Vieira</surname><given-names>PMM</given-names></name><name><surname>Mori</surname><given-names>MAS</given-names></name><name><surname>Farias</surname><given-names>AS</given-names></name><name><surname>Vinolo</surname><given-names>MAR</given-names></name><name><surname>Leal</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Microbiota-derived short-chain fatty acids do not interfere with SARS-CoV-2 infection of human colonic samples</article-title><source>Gut Microbes</source><volume>13</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1080/19490976.2021.1874740</pub-id><pub-id pub-id-type="pmid">33550892</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pontelli</surname><given-names>MC</given-names></name><name><surname>Castro</surname><given-names>ÍA</given-names></name><name><surname>Martins</surname><given-names>RB</given-names></name><name><surname>La Serra</surname><given-names>L</given-names></name><name><surname>Veras</surname><given-names>FP</given-names></name><name><surname>Nascimento</surname><given-names>DC</given-names></name><name><surname>Silva</surname><given-names>CM</given-names></name><name><surname>Cardoso</surname><given-names>RS</given-names></name><name><surname>Rosales</surname><given-names>R</given-names></name><name><surname>Gomes</surname><given-names>R</given-names></name><name><surname>Lima</surname><given-names>TM</given-names></name><name><surname>Souza</surname><given-names>JP</given-names></name><name><surname>Vitti</surname><given-names>BC</given-names></name><name><surname>Caetité</surname><given-names>DB</given-names></name><name><surname>de Lima</surname><given-names>MHF</given-names></name><name><surname>Stumpf</surname><given-names>SD</given-names></name><name><surname>Thompson</surname><given-names>CE</given-names></name><name><surname>Bloyet</surname><given-names>L-M</given-names></name><name><surname>Toller-Kawahisa</surname><given-names>JE</given-names></name><name><surname>Giannini</surname><given-names>MC</given-names></name><name><surname>Bonjorno</surname><given-names>LP</given-names></name><name><surname>Lopes</surname><given-names>MIF</given-names></name><name><surname>Batah</surname><given-names>SS</given-names></name><name><surname>Siyuan</surname><given-names>L</given-names></name><name><surname>Luppino-Assad</surname><given-names>R</given-names></name><name><surname>Almeida</surname><given-names>SCL</given-names></name><name><surname>Oliveira</surname><given-names>FR</given-names></name><name><surname>Benatti</surname><given-names>MN</given-names></name><name><surname>Pontes</surname><given-names>LLF</given-names></name><name><surname>Santana</surname><given-names>RC</given-names></name><name><surname>Vilar</surname><given-names>FC</given-names></name><name><surname>Auxiliadora-Martins</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>P-Y</given-names></name><name><surname>Cunha</surname><given-names>TM</given-names></name><name><surname>Calado</surname><given-names>RT</given-names></name><name><surname>Alves-Filho</surname><given-names>JC</given-names></name><name><surname>Zamboni</surname><given-names>DS</given-names></name><name><surname>Fabro</surname><given-names>AT</given-names></name><name><surname>Louzada-Junior</surname><given-names>P</given-names></name><name><surname>Oliveira</surname><given-names>RDR</given-names></name><name><surname>Whelan</surname><given-names>SPJ</given-names></name><name><surname>Cunha</surname><given-names>FQ</given-names></name><name><surname>Arruda</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2 productively infects primary human immune system cells in vitro and in COVID-19 patients</article-title><source>Journal of Molecular Cell Biology</source><volume>14</volume><elocation-id>mjac021</elocation-id><pub-id pub-id-type="doi">10.1093/jmcb/mjac021</pub-id><pub-id pub-id-type="pmid">35451490</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radom</surname><given-names>F</given-names></name><name><surname>Plückthun</surname><given-names>A</given-names></name><name><surname>Paci</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Assessment of ab initio models of protein complexes by molecular dynamics</article-title><source>PLOS Computational Biology</source><volume>14</volume><elocation-id>e1006182</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1006182</pub-id><pub-id pub-id-type="pmid">29864135</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbiani</surname><given-names>DF</given-names></name><name><surname>Gaebler</surname><given-names>C</given-names></name><name><surname>Muecksch</surname><given-names>F</given-names></name><name><surname>Lorenzi</surname><given-names>JCC</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Cho</surname><given-names>A</given-names></name><name><surname>Agudelo</surname><given-names>M</given-names></name><name><surname>Barnes</surname><given-names>CO</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Finkin</surname><given-names>S</given-names></name><name><surname>Hägglöf</surname><given-names>T</given-names></name><name><surname>Oliveira</surname><given-names>TY</given-names></name><name><surname>Viant</surname><given-names>C</given-names></name><name><surname>Hurley</surname><given-names>A</given-names></name><name><surname>Hoffmann</surname><given-names>HH</given-names></name><name><surname>Millard</surname><given-names>KG</given-names></name><name><surname>Kost</surname><given-names>RG</given-names></name><name><surname>Cipolla</surname><given-names>M</given-names></name><name><surname>Gordon</surname><given-names>K</given-names></name><name><surname>Bianchini</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>ST</given-names></name><name><surname>Ramos</surname><given-names>V</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Dizon</surname><given-names>J</given-names></name><name><surname>Shimeliovich</surname><given-names>I</given-names></name><name><surname>Mendoza</surname><given-names>P</given-names></name><name><surname>Hartweger</surname><given-names>H</given-names></name><name><surname>Nogueira</surname><given-names>L</given-names></name><name><surname>Pack</surname><given-names>M</given-names></name><name><surname>Horowitz</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>F</given-names></name><name><surname>Weisblum</surname><given-names>Y</given-names></name><name><surname>Michailidis</surname><given-names>E</given-names></name><name><surname>Ashbrook</surname><given-names>AW</given-names></name><name><surname>Waltari</surname><given-names>E</given-names></name><name><surname>Pak</surname><given-names>JE</given-names></name><name><surname>Huey-Tubman</surname><given-names>KE</given-names></name><name><surname>Koranda</surname><given-names>N</given-names></name><name><surname>Hoffman</surname><given-names>PR</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Hatziioannou</surname><given-names>T</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Bieniasz</surname><given-names>PD</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Convergent antibody responses to SARS-CoV-2 in convalescent individuals</article-title><source>Nature</source><volume>584</volume><fpage>437</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2456-9</pub-id><pub-id pub-id-type="pmid">32555388</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roe</surname><given-names>DR</given-names></name><name><surname>Cheatham</surname><given-names>TE</given-names><suffix>III</suffix></name></person-group><year iso-8601-date="2013">2013</year><article-title>PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data</article-title><source>Journal of Chemical Theory and Computation</source><volume>9</volume><fpage>3084</fpage><lpage>3095</lpage><pub-id pub-id-type="doi">10.1021/ct400341p</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saccon</surname><given-names>TD</given-names></name><name><surname>Mousovich-Neto</surname><given-names>F</given-names></name><name><surname>Ludwig</surname><given-names>RG</given-names></name><name><surname>Carregari</surname><given-names>VC</given-names></name><name><surname>Dos Anjos Souza</surname><given-names>AB</given-names></name><name><surname>Dos Passos</surname><given-names>ASC</given-names></name><name><surname>Martini</surname><given-names>MC</given-names></name><name><surname>Barbosa</surname><given-names>PP</given-names></name><name><surname>de Souza</surname><given-names>GF</given-names></name><name><surname>Muraro</surname><given-names>SP</given-names></name><name><surname>Forato</surname><given-names>J</given-names></name><name><surname>Amorim</surname><given-names>MR</given-names></name><name><surname>Marques</surname><given-names>RE</given-names></name><name><surname>Veras</surname><given-names>FP</given-names></name><name><surname>Barreto</surname><given-names>E</given-names></name><name><surname>Gonçalves</surname><given-names>TT</given-names></name><name><surname>Paiva</surname><given-names>IM</given-names></name><name><surname>Fazolini</surname><given-names>NPB</given-names></name><name><surname>Onodera</surname><given-names>CMK</given-names></name><name><surname>Martins Junior</surname><given-names>RB</given-names></name><name><surname>de Araújo</surname><given-names>PHC</given-names></name><name><surname>Batah</surname><given-names>SS</given-names></name><name><surname>Viana</surname><given-names>RMM</given-names></name><name><surname>de Melo</surname><given-names>DM</given-names></name><name><surname>Fabro</surname><given-names>AT</given-names></name><name><surname>Arruda</surname><given-names>E</given-names></name><name><surname>Queiroz Cunha</surname><given-names>F</given-names></name><name><surname>Cunha</surname><given-names>TM</given-names></name><name><surname>Pretti</surname><given-names>MAM</given-names></name><name><surname>Smith</surname><given-names>BJ</given-names></name><name><surname>Marques-Souza</surname><given-names>H</given-names></name><name><surname>Knittel</surname><given-names>TL</given-names></name><name><surname>Ruiz</surname><given-names>GP</given-names></name><name><surname>Profeta</surname><given-names>GS</given-names></name><name><surname>Fontes-Cal</surname><given-names>TCM</given-names></name><name><surname>Boroni</surname><given-names>M</given-names></name><name><surname>Vinolo</surname><given-names>MAR</given-names></name><name><surname>Farias</surname><given-names>AS</given-names></name><name><surname>Moraes-Vieira</surname><given-names>PMM</given-names></name><name><surname>Bizzacchi</surname><given-names>JMA</given-names></name><name><surname>Teesalu</surname><given-names>T</given-names></name><name><surname>Chaim</surname><given-names>FDM</given-names></name><name><surname>Cazzo</surname><given-names>E</given-names></name><name><surname>Chaim</surname><given-names>EA</given-names></name><name><surname>Proença-Módena</surname><given-names>JL</given-names></name><name><surname>Martins-de-Souza</surname><given-names>D</given-names></name><name><surname>Osako</surname><given-names>MK</given-names></name><name><surname>Leiria</surname><given-names>LO</given-names></name><name><surname>Mori</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2 infects adipose tissue in a fat depot- and viral lineage-dependent manner</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>5722</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-33218-8</pub-id><pub-id pub-id-type="pmid">36175400</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaik</surname><given-names>MM</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Rits-Volloch</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural basis of coreceptor recognition by HIV-1 envelope spike</article-title><source>Nature</source><volume>565</volume><fpage>318</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0804-9</pub-id><pub-id pub-id-type="pmid">30542158</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>K</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Aihara</surname><given-names>H</given-names></name><name><surname>Geng</surname><given-names>Q</given-names></name><name><surname>Auerbach</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis of receptor recognition by SARS-CoV-2</article-title><source>Nature</source><volume>581</volume><fpage>221</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2179-y</pub-id><pub-id pub-id-type="pmid">32225175</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>X</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Xue</surname><given-names>R</given-names></name><name><surname>Ai</surname><given-names>N</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>scCATCH: Automatic Annotation on Cell Types of Clusters from Single-Cell RNA Sequencing Data</article-title><source>iScience</source><volume>23</volume><elocation-id>100882</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2020.100882</pub-id><pub-id pub-id-type="pmid">32062421</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>XR</given-names></name><name><surname>Geng</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>SF</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Min</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>RD</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>XS</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>JK</given-names></name><name><surname>Yang</surname><given-names>XL</given-names></name><name><surname>Liu</surname><given-names>MQ</given-names></name><name><surname>Gong</surname><given-names>QC</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Guan</surname><given-names>ZQ</given-names></name><name><surname>Li</surname><given-names>HL</given-names></name><name><surname>Zheng</surname><given-names>ZH</given-names></name><name><surname>Shi</surname><given-names>ZL</given-names></name><name><surname>Zhang</surname><given-names>HL</given-names></name><name><surname>Peng</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>ACE2-independent infection of T lymphocytes by SARS-CoV-2</article-title><source>Signal Transduction and Targeted Therapy</source><volume>7</volume><elocation-id>83</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-022-00919-x</pub-id><pub-id pub-id-type="pmid">35277473</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>WM</given-names></name><name><surname>Amorim</surname><given-names>MR</given-names></name><name><surname>Sesti-Costa</surname><given-names>R</given-names></name><name><surname>Coimbra</surname><given-names>LD</given-names></name><name><surname>Brunetti</surname><given-names>NS</given-names></name><name><surname>Toledo-Teixeira</surname><given-names>DA</given-names></name><name><surname>de Souza</surname><given-names>GF</given-names></name><name><surname>Muraro</surname><given-names>SP</given-names></name><name><surname>Parise</surname><given-names>PL</given-names></name><name><surname>Barbosa</surname><given-names>PP</given-names></name><name><surname>Bispo-Dos-Santos</surname><given-names>K</given-names></name><name><surname>Mofatto</surname><given-names>LS</given-names></name><name><surname>Simeoni</surname><given-names>CL</given-names></name><name><surname>Claro</surname><given-names>IM</given-names></name><name><surname>Duarte</surname><given-names>ASS</given-names></name><name><surname>Coletti</surname><given-names>TM</given-names></name><name><surname>Zangirolami</surname><given-names>AB</given-names></name><name><surname>Costa-Lima</surname><given-names>C</given-names></name><name><surname>Gomes</surname><given-names>ABSP</given-names></name><name><surname>Buscaratti</surname><given-names>LI</given-names></name><name><surname>Sales</surname><given-names>FC</given-names></name><name><surname>Costa</surname><given-names>VA</given-names></name><name><surname>Franco</surname><given-names>LAM</given-names></name><name><surname>Candido</surname><given-names>DS</given-names></name><name><surname>Pybus</surname><given-names>OG</given-names></name><name><surname>de Jesus</surname><given-names>JG</given-names></name><name><surname>Silva</surname><given-names>CAM</given-names></name><name><surname>Ramundo</surname><given-names>MS</given-names></name><name><surname>Ferreira</surname><given-names>GM</given-names></name><name><surname>Pinho</surname><given-names>MC</given-names></name><name><surname>Souza</surname><given-names>LM</given-names></name><name><surname>Rocha</surname><given-names>EC</given-names></name><name><surname>Andrade</surname><given-names>PS</given-names></name><name><surname>Crispim</surname><given-names>MAE</given-names></name><name><surname>Maktura</surname><given-names>GC</given-names></name><name><surname>Manuli</surname><given-names>ER</given-names></name><name><surname>Santos</surname><given-names>MNN</given-names></name><name><surname>Camilo</surname><given-names>CC</given-names></name><name><surname>Angerami</surname><given-names>RN</given-names></name><name><surname>Moretti</surname><given-names>ML</given-names></name><name><surname>Spilki</surname><given-names>FR</given-names></name><name><surname>Arns</surname><given-names>CW</given-names></name><name><surname>Addas-Carvalho</surname><given-names>M</given-names></name><name><surname>Benites</surname><given-names>BD</given-names></name><name><surname>Vinolo</surname><given-names>MAR</given-names></name><name><surname>Mori</surname><given-names>MAS</given-names></name><name><surname>Gaburo</surname><given-names>N</given-names></name><name><surname>Dye</surname><given-names>C</given-names></name><name><surname>Marques-Souza</surname><given-names>H</given-names></name><name><surname>Marques</surname><given-names>RE</given-names></name><name><surname>Farias</surname><given-names>AS</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Faria</surname><given-names>NR</given-names></name><name><surname>Sabino</surname><given-names>EC</given-names></name><name><surname>Granja</surname><given-names>F</given-names></name><name><surname>Proença-Módena</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study</article-title><source>The Lancet. Microbe</source><volume>2</volume><fpage>e527</fpage><lpage>e535</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(21)00129-4</pub-id><pub-id pub-id-type="pmid">34258603</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Hafemeister</surname><given-names>C</given-names></name><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Mauck</surname><given-names>WM</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Stoeckius</surname><given-names>M</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comprehensive integration of single-cell data</article-title><source>Cell</source><volume>177</volume><fpage>1888</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.031</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavares</surname><given-names>LA</given-names></name><name><surname>da Silva</surname><given-names>EML</given-names></name><name><surname>da Silva-Januário</surname><given-names>ME</given-names></name><name><surname>Januário</surname><given-names>YC</given-names></name><name><surname>de Cavalho</surname><given-names>JV</given-names></name><name><surname>Czernisz</surname><given-names>ÉS</given-names></name><name><surname>Mardones</surname><given-names>GA</given-names></name><name><surname>daSilva</surname><given-names>LLP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CD4 down-regulation by HIV-1 Nef reveals distinct roles for γ1 and γ2 subunits of AP-1 complex in protein trafficking</article-title><source>Journal of Cell Science</source><volume>130</volume><fpage>429</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1242/jcs.192104</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavares</surname><given-names>LA</given-names></name><name><surname>de Carvalho</surname><given-names>JV</given-names></name><name><surname>Costa</surname><given-names>CS</given-names></name><name><surname>Silveira</surname><given-names>RM</given-names></name><name><surname>de Carvalho</surname><given-names>AN</given-names></name><name><surname>Donadi</surname><given-names>EA</given-names></name><name><surname>daSilva</surname><given-names>LLP</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Two Functional Variants of AP-1 Complexes Composed of either γ2 or γ1 Subunits Are Independently Required for Major Histocompatibility Complex Class I Downregulation by HIV-1 Nef</article-title><source>Journal of Virology</source><volume>94</volume><elocation-id>e02039-19</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.02039-19</pub-id><pub-id pub-id-type="pmid">31915283</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoms</surname><given-names>M</given-names></name><name><surname>Buschauer</surname><given-names>R</given-names></name><name><surname>Ameismeier</surname><given-names>M</given-names></name><name><surname>Koepke</surname><given-names>L</given-names></name><name><surname>Denk</surname><given-names>T</given-names></name><name><surname>Hirschenberger</surname><given-names>M</given-names></name><name><surname>Kratzat</surname><given-names>H</given-names></name><name><surname>Hayn</surname><given-names>M</given-names></name><name><surname>Mackens-Kiani</surname><given-names>T</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Straub</surname><given-names>JH</given-names></name><name><surname>Stürzel</surname><given-names>CM</given-names></name><name><surname>Fröhlich</surname><given-names>T</given-names></name><name><surname>Berninghausen</surname><given-names>O</given-names></name><name><surname>Becker</surname><given-names>T</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name><name><surname>Sparrer</surname><given-names>KMJ</given-names></name><name><surname>Beckmann</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2</article-title><source>Science</source><volume>369</volume><fpage>1249</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.1126/science.abc8665</pub-id><pub-id pub-id-type="pmid">32680882</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thul</surname><given-names>PJ</given-names></name><name><surname>Lindskog</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The human protein atlas: A spatial map of the human proteome</article-title><source>Protein Science</source><volume>27</volume><fpage>233</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1002/pro.3307</pub-id><pub-id pub-id-type="pmid">28940711</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Zundert</surname><given-names>GCP</given-names></name><name><surname>Rodrigues</surname><given-names>JP</given-names></name><name><surname>Trellet</surname><given-names>M</given-names></name><name><surname>Schmitz</surname><given-names>C</given-names></name><name><surname>Kastritis</surname><given-names>PL</given-names></name><name><surname>Karaca</surname><given-names>E</given-names></name><name><surname>Melquiond</surname><given-names>ASJ</given-names></name><name><surname>van Dijk</surname><given-names>M</given-names></name><name><surname>de Vries</surname><given-names>SJ</given-names></name><name><surname>Bonvin</surname><given-names>AMJJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes</article-title><source>Journal of Molecular Biology</source><volume>428</volume><fpage>720</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2015.09.014</pub-id><pub-id pub-id-type="pmid">26410586</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Niu</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Qiao</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Yuen</surname><given-names>K-Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2</article-title><source>Cell</source><volume>181</volume><fpage>894</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.045</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Allen</surname><given-names>JD</given-names></name><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name><name><surname>Crispin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Site-specific glycan analysis of the SARS-CoV-2 spike</article-title><source>Science</source><volume>369</volume><fpage>330</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1126/science.abb9983</pub-id><pub-id pub-id-type="pmid">32366695</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Won</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>TY</given-names></name><name><surname>Park</surname><given-names>MG</given-names></name><name><surname>Choi</surname><given-names>BY</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>VN</given-names></name><name><surname>Lee</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19)</article-title><source>Experimental Neurobiology</source><volume>29</volume><fpage>107</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.5607/en20009</pub-id><pub-id pub-id-type="pmid">32156101</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Choi</surname><given-names>YK</given-names></name><name><surname>Park</surname><given-names>T</given-names></name><name><surname>Tanveer</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Kern</surname><given-names>NR</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Yeom</surname><given-names>MS</given-names></name><name><surname>Croll</surname><given-names>TI</given-names></name><name><surname>Seok</surname><given-names>C</given-names></name><name><surname>Im</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Developing a Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein Model in a Viral Membrane</article-title><source>The Journal of Physical Chemistry. B</source><volume>124</volume><fpage>7128</fpage><lpage>7137</lpage><pub-id pub-id-type="doi">10.1021/acs.jpcb.0c04553</pub-id><pub-id pub-id-type="pmid">32559081</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Goldsmith</surname><given-names>JA</given-names></name><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Abiona</surname><given-names>O</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Hendrickson</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Dimeric association and segmental variability in the structure of human CD4</article-title><source>Nature</source><volume>387</volume><fpage>527</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1038/387527a0</pub-id><pub-id pub-id-type="pmid">9168119</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Tsueng</surname><given-names>G</given-names></name><name><surname>Afrasiabi</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>AI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>BioGPS: building your own mash-up of gene annotations and expression profiles</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>D313</fpage><lpage>D316</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1104</pub-id><pub-id pub-id-type="pmid">26578587</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>XN</given-names></name><name><surname>Screaton</surname><given-names>GR</given-names></name><name><surname>McMichael</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Virus infections: escape, resistance, and counterattack</article-title><source>Immunity</source><volume>15</volume><fpage>867</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(01)00255-2</pub-id><pub-id pub-id-type="pmid">11754809</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Nilsson-Payant</surname><given-names>BE</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Duan</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Jaffré</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Harschnitz</surname><given-names>O</given-names></name><name><surname>Redmond</surname><given-names>D</given-names></name><name><surname>Houghton</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Naji</surname><given-names>A</given-names></name><name><surname>Ciceri</surname><given-names>G</given-names></name><name><surname>Guttikonda</surname><given-names>S</given-names></name><name><surname>Bram</surname><given-names>Y</given-names></name><name><surname>Nguyen</surname><given-names>D-HT</given-names></name><name><surname>Cioffi</surname><given-names>M</given-names></name><name><surname>Chandar</surname><given-names>V</given-names></name><name><surname>Hoagland</surname><given-names>DA</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Lyden</surname><given-names>D</given-names></name><name><surname>Borczuk</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>HJ</given-names></name><name><surname>Studer</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>FC</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>tenOever</surname><given-names>BR</given-names></name><name><surname>Evans</surname><given-names>T</given-names></name><name><surname>Schwartz</surname><given-names>RE</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids</article-title><source>Cell Stem Cell</source><volume>27</volume><fpage>125</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2020.06.015</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>NC</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Lee</surname><given-names>CCD</given-names></name><name><surname>So</surname><given-names>RTY</given-names></name><name><surname>Lv</surname><given-names>H</given-names></name><name><surname>Mok</surname><given-names>CKP</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV</article-title><source>Science</source><volume>368</volume><fpage>630</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1126/science.abb7269</pub-id><pub-id pub-id-type="pmid">32245784</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>Y</given-names></name><name><surname>Nabar</surname><given-names>NR</given-names></name><name><surname>Shi</surname><given-names>CS</given-names></name><name><surname>Kamenyeva</surname><given-names>O</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Hwang</surname><given-names>IY</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Kehrl</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>SARS-Coronavirus Open Reading Frame-3a drives multimodal necrotic cell death</article-title><source>Cell Death &amp; Disease</source><volume>9</volume><elocation-id>904</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-018-0917-y</pub-id><pub-id pub-id-type="pmid">30185776</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Ling</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Yi</surname><given-names>Z</given-names></name><name><surname>Jia</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Viral and host factors related to the clinical outcome of COVID-19</article-title><source>Nature</source><volume>583</volume><fpage>437</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2355-0</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Xiang</surname><given-names>H</given-names></name><name><surname>Ogg</surname><given-names>G</given-names></name><name><surname>Ho</surname><given-names>LP</given-names></name><name><surname>McMichael</surname><given-names>A</given-names></name><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Knight</surname><given-names>JC</given-names></name><name><surname>Dong</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>139834</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.139834</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>HY</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>CX</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>XC</given-names></name><name><surname>Yang</surname><given-names>XP</given-names></name><name><surname>Dong</surname><given-names>XQ</given-names></name><name><surname>Zheng</surname><given-names>YT</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients</article-title><source>Cellular &amp; Molecular Immunology</source><volume>17</volume><fpage>541</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0401-3</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84790.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van de Veerdonk</surname><given-names>Frank L</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Radboud University Nijmegen Medical Centre</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2020.09.25.20200329" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2020.09.25.20200329"/></front-stub><body><p>This study represents an important contribution where SARS-CoV-2 infection of T-helper cells is implicated and found to be mediated by CD4. It identifies the interaction between spike RBD domain and N Terminal domain of CD4 molecule as the specific viral attachment strategy. This solid paper also provides a potential usefulness for future work in understanding how viruses mediate infection of T cells.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84790.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>van de Veerdonk</surname><given-names>Frank L</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Radboud University Nijmegen Medical Centre</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2020.09.25.20200329">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2020.09.25.20200329v2">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;SARS-CoV-2 Uses CD4 to Infect T Helper Lymphocytes&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jos van der Meer as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Comments and suggestions:</p><p>1. A weakness of the paper is the reference citations.</p><p>Please be consistent in maintaining the citation style and numbering in the manuscript.</p><p>2. Although the extended Figure 9 suggests the expression of a multitude panel of gene expression, including apoptotic genes, the authors could not provide a piece of direct evidence to show how CD4 T cell death happens. What is the underlying mechanism of cell death? Is it by necrosis or apoptosis or pyroptosis? Please discuss.</p><p>3. Some previous studies suggested that lymphocytopenia in COVID infection could be due to impaired T cell proliferation or extravasation of T cells into tissue. The exact mechanism for lymphocytopenia should be discussed.</p><p>4. The data on CREB-1 Ser 133 in Figure 4E is not sufficiently convincing. It is difficult to understand what is the difference between every three lanes within mock and SARS CoV-2 infection. There is a pCREB band in lane 5 (2nd lane of CoV-2), but not in the other two. Please clarify.</p><p>5. Please add more specific information on the Insitu hybridization method. What is PK in the Insitu hybridization method? '…a couple of more washes'. Please be specific on experimental details.</p><p>6. Detection of antisense strand: Any reason to use 4% agarose gel? Is it due to the difficulty to detect the smaller size of the amplicon?</p><p>7. Immunoblotting: More experimental details are required. How many cells were infected or what is the total number of cells started with to get MOI=1? What is the exact time point used in Figure 4. E?</p><p>8. Immunofluorescence: Normally immunofluorescence protocol suggests 5% BSA for blocking. Is there any specific reason to use 1% BSA for blocking?</p><p>9. Transmission electron microscopy: More details on cacodylate buffer with calcium chloride in terms of concentration/molarity.</p><p>10. RNA extraction and cDNA synthesis: Please specify the sample volumes used for extracting the RNA. Specify the quantity of total RNA or cDNA used for qRT PCR.</p><p>11. What is the housekeeping gene HPRT? Please expand it.</p><p>12. Please watch the abbreviations and provide the expanded version wherever required. For example Single-cell mRNA seq: What is CCA? What is PCA?</p><p>13. It is interesting from a computational biology perspective that if GO database is removed (too unvalidated), and &quot;Cell surface&quot; component of the Jensen database (considering its more dedicated &quot;Plasma membrane&quot; and &quot;External side of plasma membrane&quot; components considered in the work) out of the Venn diagram (Extended Data Figure 3), then what will be left is more interaction partners shared between the remaining 3 databases. Interestingly, these additional partners would include CD8A and CD8B. However, the authors show that the interaction was experimentally noted to happen with CD4<sup>+</sup> T cells but not with CD8<sup>+</sup> ones. This warrants some discussion on why this might be the case. Moreover, what would be the computational docking/MD results if the authors were to attempt modelling an interaction between the spike glycoprotein and CD8? Would they not arrive at stable complexes with the MD workflow and 4 Å cutoff for temperature-induced stability scrutinization, that would be extra validation and weight on the adopted computational scheme for the discovery.</p><p>14. Looking at the last complex in Figure 2, where the full-length sCov2 is recovered on top of the modelled fragment, one can see some additional interaction points or potential clashes with CD4 NTD. Were some of the models discarded on the ground of the orientation between CD4 NTD and sCov2 RBD being incompatible with the full length sCov2 due to possible steric clashes?</p><p>15. The 4 Å cutoff for the temperature gradient-based structural stability check sounds reasonable, but would be more justifiable if the authors would also present a histogram of all RMSDs (of final aberrations) for all the tried models and show how outlying the 4 Å is in the whole distribution, additionally attributing a p-value on the selected cutoff.</p><p>16. &quot;Methods&quot; section, &quot;Target selection&quot; subsection. Please, define/describe LR in the text for the benefit of the readers.</p><p>17. &quot;Methods&quot; section, the last &quot;Molecular Dynamics Simulations&quot; subsection. There is a sentence that has &quot;… for the data contained in Figure Sx…&quot;, please correct which supplementary figure is meant, as likely the Sx notation is left from the earlier drafts of the manuscript.</p><p>18. Figure 2 caption, an extra &quot;.&quot; after (B).</p><p>19. Figure 2. It would help if model 95 and model 148 were brought roughly in the same spatial orientation as the final CD4 NTD and full sCov2 RBD model, to aid the readers in matching and getting more insight.</p><p>20. Extended Data Figure 3. In Figure A (Venn diagram), at &quot;Plasma membrane Jensen compartments&quot; notation closing bracket is missing.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84790.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Comments and suggestions:</p><p>1. A weakness of the paper is the reference citations.</p><p>Please be consistent in maintaining the citation style and numbering in the manuscript.</p></disp-quote><p>We have edited the references according to the <italic>eLife</italic> citation style.</p><disp-quote content-type="editor-comment"><p>2. Although the extended Figure 9 suggests the expression of a multitude panel of gene expression, including apoptotic genes, the authors could not provide a piece of direct evidence to show how CD4 T cell death happens. What is the underlying mechanism of cell death? Is it by necrosis or apoptosis or pyroptosis? Please discuss.</p></disp-quote><p>We would like to thank the Reviewer for the question, which gave us the opportunity to review the text and include a discussion about this topic in the paper. Please see sentences between lines 240 and 246. SARS-CoV-2 can induce cell death by different mechanisms, depending on the infected cell type and the microenvironment and inflammatory condition where these cells are inserted. For example, SARS-CoV-2 can induce apoptosis in different cell lines through stimulation of autophagy via suppression of mTOR signaling (DOI: 10.1016/j.bbadis.2021.166260). SARS-CoV-2 can also induce inflammasome activation and cell death by pyroptosis in primary monocytes and PBMCs from COVID-19 patients (DOI: 10.1084/jem.20201707). Immunomodulatory drugs that inhibit inflammasome pathways impair SARS-CoV-2 replication in monocytes and other cell types (DOI: 10.1126/sciadv.abo5400) and may have beneficial effects to the treatment of COVID-19. In addition, SARS-CoV-2 drives multimodal necrosis in epithelial respiratory and kidney cell lines by a mechanism dependent on Open Reading Frame-3a of the virus (doi:10.1038/s41419‐018‐0917‐y) and it is able to induce PANoptosis by a mechanism dependent on ISG production, such as Z-DNA-binding protein 1 (ZBP1), in a context of cytokine storm and IFN-I treatment (10.1126/sciimmunol.abo6294). Thus, cell death induced by SARS-CoV-2 appears to play a pivotal role in the pathogenesis of COVID-19. Interestingly and in line with this idea, proinflammatory cytokines produced by SARS-CoV-2-infected apoptotic cells inhibit the expression of efferocytic receptors and impairs the continual process of clearance of dying cells by macrophages (DOI: 10.7554/<italic>eLife</italic>.74443). In the present paper, we demonstrated that SARS-CoV-2 can infect and induce cell death of CD4 T cells. Although the mechanisms of cell death have not been explored in depth in this article, data in the literature suggests that apoptosis is the mechanism underlying SARS-CoV-2-infected T cell death (DOI: 10.1093/jmcb/mjac021).</p><disp-quote content-type="editor-comment"><p>3. Some previous studies suggested that lymphocytopenia in COVID infection could be due to impaired T cell proliferation or extravasation of T cells into tissue. The exact mechanism for lymphocytopenia should be discussed.</p></disp-quote><p>Lymphocytopenia is a common characteristic of COVID-19 (https://www.nature.com/articles/s41392-020-0148-4). The decrease of the number of circulating lymphocytes might be due to innumerous factors, such as cell death, migration into the inflamed tissue as well as by promoting systemic inflammation and direct neutralization in human spleen and lymph nodes (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2021.661052">https://doi.org/10.3389/fimmu.2021.661052</ext-link>). Single-cell analysis demonstrated that lymphocytes are not the main infiltrated cell population in the infected tissue (see figure 1E). Hence, it is likely that the decrease in lymphocyte count is attributed to both infected T cell death and dysfunctional T cells resulting from the inflammatory cytokine storm. This discussion has been incorporated into the manuscript.</p><disp-quote content-type="editor-comment"><p>4. The data on CREB-1 Ser 133 in Figure 4E is not sufficiently convincing. It is difficult to understand what is the difference between every three lanes within mock and SARS CoV-2 infection. There is a pCREB band in lane 5 (2nd lane of CoV-2), but not in the other two. Please clarify.</p></disp-quote><p>Each lane in the western blotting experiment represents a different sample and each group were done in triplicate (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). Hence, a combination of experimental and biological variability, which is common when using human samples, explains the differences between the lanes, particularly in the 5th lane of pCREB.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84790-sa2-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>5. Please add more specific information on the Insitu hybridization method. What is PK in the Insitu hybridization method? '…a couple of more washes'. Please be specific on experimental details.</p></disp-quote><p>PK is an abbreviation for Proteinase K (https://www.sigmaaldrich.com/BR/pt/product/mm/124568) used in the antigen retrieval step by digesting mRNA bound proteins that could prevent the DNA probes to hybridize to their target mRNA. As for the wash steps after fixation with 4% PFA, three washes were performed to remove possible fixative residues. More specific information was added to the manuscript.</p><disp-quote content-type="editor-comment"><p>6. Detection of antisense strand: Any reason to use 4% agarose gel? Is it due to the difficulty to detect the smaller size of the amplicon?</p></disp-quote><p>The 4% agarose gel was employed in this protocol to attain the necessary resolution for discriminating between the sense and antisense strands based on their size difference. The difference in size between the two strands is only 21 nucleotides, which is caused by the non-viral tag present in the antisense strand. To effectively separate the small DNA fragments, a higher percentage agarose gel was required as it provides better resolution.</p><disp-quote content-type="editor-comment"><p>7. Immunoblotting: More experimental details are required. How many cells were infected or what is the total number of cells started with to get MOI=1? What is the exact time point used in Figure 4. E?</p></disp-quote><p>Most of the experiments were done with one million sorted CD3+CD4<sup>+</sup> live cells plated over a well of a 48-well plate. For proteomic and immunoblotting experiments, four million live CD3+CD4<sup>+</sup> cells were used. All experiments with SARS-CoV-2 were done in a biosafety level 3 laboratory (BSL-3) located in the Institute of Biology from the University Campinas. This information was clarified in the text.</p><disp-quote content-type="editor-comment"><p>8. Immunofluorescence: Normally immunofluorescence protocol suggests 5% BSA for blocking. Is there any specific reason to use 1% BSA for blocking?</p></disp-quote><p>Percentage of BSA for blocking in immunofluorescence usually varies from 1-5%. We used different concentrations and decided to follow the manufacturer's suggestion (https://www.abcam.com/protocols/immunocytochemistry-immunofluorescence-protocol).</p><disp-quote content-type="editor-comment"><p>9. Transmission electron microscopy: More details on cacodylate buffer with calcium chloride in terms of concentration/molarity.</p></disp-quote><p>We added the following sentence to the manuscript:</p><p>“T lymphocyte cell cultures were pelleted by centrifugation at 500 x g for 10 min. Cell culture supernatant was removed and cells were resuspended in 100 µL of the fixative solution, which consisted of 1 M sodium cacodylate aqueous solution supplemented with 2.5% v/v glutaraldehyde and 3 mM calcium chloride at pH 7.2, and kept overnight (16h) at 4°C”.</p><disp-quote content-type="editor-comment"><p>10. RNA extraction and cDNA synthesis: Please specify the sample volumes used for extracting the RNA. Specify the quantity of total RNA or cDNA used for qRT PCR.</p></disp-quote><p>We included more information in the text regarding the methods for RNA extraction and cDNA synthesis. Briefly, pelleted cells were resuspended in 200 µL of TRI Reagent and the RNA extraction performed following the manufacturer's instructions. 500 ng of RNA was converted into cDNA. The cDNA final concentration was 25 ng/μL and qPCR reaction was performed using 15 ng of cDNA.</p><disp-quote content-type="editor-comment"><p>11. What is the housekeeping gene HPRT? Please expand it.</p></disp-quote><p>The HPRT is a gene that encodes the hypoxanthine phosphoribosyltransferase 1 protein, an enzyme responsible for recycling purines (purine salvage pathway) in DNA molecules. This enzyme catalyzes conversion of hypoxanthine to inosine monophosphate (IMP) and guanine to guanosine monophosphate (GMP), when transferring phosphoribose from phosphoribosyl pyrophosphate (PRPP). This gene is present in all somatic cells and is considered a housekeeping gene because GTP is necessary for DNA synthesis and cellular energy. For lymphocytes, especially in non-activated conditions, HPRT has shown to be a reliable housekeeping gene (https://pubmed.ncbi.nlm.nih.gov/35645343/).</p><disp-quote content-type="editor-comment"><p>12. Please watch the abbreviations and provide the expanded version wherever required. For example Single-cell mRNA seq: What is CCA? What is PCA?</p></disp-quote><p>We thank the Reviewer for pointing this out. Abbreviations were defined as they appeared for the first time.</p><disp-quote content-type="editor-comment"><p>13. It is interesting from a computational biology perspective that if GO database is removed (too unvalidated), and &quot;Cell surface&quot; component of the Jensen database (considering its more dedicated &quot;Plasma membrane&quot; and &quot;External side of plasma membrane&quot; components considered in the work) out of the Venn diagram (Extended Data Figure 3), then what will be left is more interaction partners shared between the remaining 3 databases. Interestingly, these additional partners would include CD8A and CD8B. However, the authors show that the interaction was experimentally noted to happen with CD4<sup>+</sup> T cells but not with CD8<sup>+</sup> ones. This warrants some discussion on why this might be the case. Moreover, what would be the computational docking/MD results if the authors were to attempt modelling an interaction between the spike glycoprotein and CD8? Would they not arrive at stable complexes with the MD workflow and 4 Å cutoff for temperature-induced stability scrutinization, that would be extra validation and weight on the adopted computational scheme for the discovery.</p></disp-quote><p>Although the Reviewer raises an interesting observation, our experiments beyond the computational prediction do not support a role for CD8 in T lymphocyte infection. Hence, we decided not to focus on a potential interaction between CD8 and SARS-CoV spike protein, although this does not exclude that the interaction may exist. Indeed, a highly stable interaction between Spike and CD8 molecules could result in a 'stable' complex that would trap the viral particles outside the cell precluding infection. This would be consistent with T CD8 cells not being infected by SARS-CoV-2. However, we would need more experiments to prove this mechanism and this is beyond the scope of this manuscript, which focuses on the interaction between spike and CD4 and its role in CD4 T cell infection.</p><disp-quote content-type="editor-comment"><p>14. Looking at the last complex in Figure 2, where the full-length sCov2 is recovered on top of the modelled fragment, one can see some additional interaction points or potential clashes with CD4 NTD. Were some of the models discarded on the ground of the orientation between CD4 NTD and sCov2 RBD being incompatible with the full length sCov2 due to possible steric clashes?</p></disp-quote><p>We appreciate the Reviewer's observation regarding the potential clashes between CD4 NTD and the full-length sCov2 in the last complex presented in Figure 2. In constructing the full model, we initially performed a superposition of the RBD domain onto the full-length sCov2. The primary criterion for selecting the final models was the kinetic stability analysis, as we aimed to identify the most stable configurations. We acknowledge that the compatibility between the docking model and the full-length sCov2, considering possible steric clashes, is an essential factor to consider. For the two most stable models, namely model95 and model148, we carefully examined their structures. In the case of model148, illustrated in Figure 2D, we did not observe any apparent clashes between CD4 NTD and the full-length sCov2.</p><p>However, we would like to emphasize that in model148, there is a possibility of CD4 NTD interacting with a second sCov2 RBD in its closed state. These interactions may involve polar interactions or mediation by water molecules when solvated. Nevertheless, based on our analysis, we do not anticipate that these few interactions play a significant role in the overall stability and function of the complex. To provide further clarity, we have made available a PyMOL session containing the structures used for the analysis in Figure 2. This session can be accessed via the following GitHub page: https://github.com/ajrferrari/CD4-RBD-interaction-models under the 'pymol-session' folder. We hope this additional information addresses the concern raised by the Reviewers.</p><disp-quote content-type="editor-comment"><p>15. The 4 Å cutoff for the temperature gradient-based structural stability check sounds reasonable, but would be more justifiable if the authors would also present a histogram of all RMSDs (of final aberrations) for all the tried models and show how outlying the 4 Å is in the whole distribution, additionally attributing a p-value on the selected cutoff.</p></disp-quote><p>We appreciate the Reviewer’s feedback regarding the justification for the 4 Å cutoff used in our temperature gradient-based structural stability check. We agree that providing additional analysis to support the chosen cutoff would enhance the validity of our findings. To further rationalize the selected cutoff, we conducted MD simulations on the sCov2 RBD and CD4 monomers independently (see figure 2—figure supplement 1e). These simulations revealed that both monomers exhibited fluctuations ranging between 2 Å and 4 Å when evaluated up to 323K. These fluctuations serve as a baseline, indicating the inherent flexibility and dynamics of the individual monomers. In our analysis, models that crossed the 4 Å cutoff at any point during the MD trajectory were considered kinetically unstable, as they exhibited higher fluctuations than the individual monomers. We have now clarified this rationale in the main text to provide a clearer understanding of the criteria used for assessing stability. To address the Reviewer’s suggestion, we have generated a histogram of the maximum backbone RMSD values for all the tried models. This histogram is provided in figure 2—figure supplement 1f.</p><p>It is important to note that the p-value obtained from the distribution of maximum RMSDs is 0.15. However, it is crucial to consider the characteristics of our evaluation process. Not all models completed the four MD steps, as some diffused away early during the evaluation. As a result, the distribution of maximum RMSDs observed is biased toward lower values. Consequently, the 4 Å cutoff appears less of an outlier than it would be if all models were equally sampled.</p><p>We believe that this additional analysis, including the histogram of maximum RMSDs, provides a more comprehensive understanding of the distribution and relative position of the 4 Å cutoff. It accounts for the limitations of the sampling process and strengthens the justification for its selection. We have revised the manuscript to include these findings, addressing the Reviewer’s' concern.</p><disp-quote content-type="editor-comment"><p>16. &quot;Methods&quot; section, &quot;Target selection&quot; subsection. Please, define/describe LR in the text for the benefit of the readers.</p></disp-quote><p>LR (likelihood ratio) has been defined in the manuscript.</p><disp-quote content-type="editor-comment"><p>17. &quot;Methods&quot; section, the last &quot;Molecular Dynamics Simulations&quot; subsection. There is a sentence that has &quot;… for the data contained in Figure Sx…&quot;, please correct which supplementary figure is meant, as likely the Sx notation is left from the earlier drafts of the manuscript.</p></disp-quote><p>We have solved this issue in the new version of the manuscript.</p><disp-quote content-type="editor-comment"><p>18. Figure 2 caption, an extra &quot;.&quot; after (B).</p></disp-quote><p>We have solved this issue in the new version of the manuscript.</p><disp-quote content-type="editor-comment"><p>19. Figure 2. It would help if model 95 and model 148 were brought roughly in the same spatial orientation as the final CD4 NTD and full sCov2 RBD model, to aid the readers in matching and getting more insight.</p></disp-quote><p>We appreciate the Reviewer's suggestion regarding Figure 2 and the importance of presenting model 95 and model 148 in a spatial orientation similar to that of the final CD4 NTD and full sCov2 RBD model. We agree that this would facilitate the readers' ability to match and gain deeper insights from the figure. In response to this valuable feedback, we have revised Figure 2 to ensure that model 95 and model 148 are now presented in a comparable spatial orientation to the final CD4 NTD and full sCov2 RBD model. This modification allows for a more straightforward visual comparison and enhances the clarity and comprehensibility of the figure. We also provide a pymol session that will allow the readers to explore in more details the models shown in Figure 2. The pymol session can be accessed via the following GitHub page: https://github.com/ajrferrari/CD4-RBD-interaction-models under the 'pymol-session' folder.</p><disp-quote content-type="editor-comment"><p>20. Extended Data Figure 3. In Figure A (Venn diagram), at &quot;Plasma membrane Jensen compartments&quot; notation closing bracket is missing.</p></disp-quote><p>We have solved this issue in the new version of the manuscript.</p></body></sub-article></article>